HALF-YEAR FINANCIAL REPORT

JUNE 30, 2024

Diasorin
The Diagnostic Specialist

Contents

DIASORIN WORLD

1. Board of Directors & Control Bodies

BOARD OF DIRECTORS (appointed on 29 April 2022)

Chairman	Michele Denegri
Deputy Chairman	Giancarlo Boschetti
Chief Executive Officer	Carlo Rosa (1)
Directors	Chen Menachem Even Stefano Altara Luca Melindo Diego Pistone Fiorella Altruda (2) André Michel Ballester (2)(3) Franco Moscetti Francesca Pasinelli (2) Roberta Somati (2) Monica Tardivo (2) Tullia Todros (2) Giovanna Pacchiana Parravicini (2)

BOARD OF STATUTORY AUDITORS

Chairman	Monica Mannino
Statutory Auditors	Ottavia Alfano Matteo Michele Sutera
Alternate Auditors	Romina Guglielmetti Cristian Tundo

INDEPENDENT AUDITORS	PricewaterhouseCoopers S.p.A.

COMMITTEES

Control, Risk and Sustainability Committee	André Michel Ballester (2) (Presidente) Franco Moscetti Roberta Somati (2)
Remuneration and Nominating Committee	Roberta Somati (2) Giancarlo Boschetti Giovanna Pacchiana Parravicini (2)
Committee for Related-Party Transactions	Roberta Somati (2) André Michel Ballester (2) Giovanna Pacchiana Parravicini (2)

(1) *General Manager*
(2) *Independent Director*
(3) *Lead Independent Director*

2. Diasorin in the world



3. The Diasorin Group

Diasorin

4. Our business

The Diasorin Group develops, produces and markets reagent kits and instruments for diagnosis and research to support a wide range of customers around the world, from testing laboratories to research bodies.

The Group's business model takes as a starting point the needs of the healthcare world and translates them, through research and innovation, into answers and diagnostic solutions.

From needs to our solutions



THE GROUP'S TECHNOLOGIES

Analysis of biological samples to detect the presence of a specific element is carried out through analyzers and biochemical reagents that are based on different and specific technologies.

Diasorin operates particularly in immunodiagnostics and molecular diagnostics. In 2021, following the acquisition of Luminex, the Group added to its technological portfolio some Life Science solutions, which use the xMAP® microsphere-based technology, sold for the development of kits or for use in the field of research and development.

1. IMMUNODIAGNOSTICS

In immunodiagnostics, Diasorin detects antibodies and antigens through platforms and tests based on CLIA technology that delivers extremely reliable and fast results and fully automates the diagnostic procedure, offering one of the widest test menus to laboratories. LIAISON® platforms (LIAISON®, LIAISON® XS, LIAISON® XL and LIAISON® XL LAS) are part of the immunodiagnostic analyzers based on CLIA technology.

1.1 PLATFORMS

LIAISON® XL

In 2023, and in the first half of 2024, the LIAISON® XL has further strengthened its penetration in international markets by leveraging its flexibility, quick and reliable results, and the wide range of both specialty and routine diagnostic tests. The LIAISON® XL platform provides highly-automated solutions, both in stand-alone configuration and through the connection to systems of the leading players in the market (XL LAS).

LIAISON® XS

Starting from 2021, following the pandemic, Diasorin has resumed the LIAISON® XS rollout, by leveraging the features that make it the most suitable platform both for laboratories with low and medium specialty test volumes and for diagnostic facilities on the territory where routine tests are performed in a centralized reference hub that offers high-throughput processing in a very short time, while specialty tests requiring close proximity to the patient are performed in smaller decentralized diagnostic facilities.

2. MOLECULAR DIAGNOSTICS

In molecular diagnostics, Diasorin offers the market two solutions based on single/low plex and multiplex technology, along with a test menu for nucleic acid amplification (DNA/RNA) of specific infectious agents to enable laboratories to detect their presence in patients' biological sample. Diasorin' s cutting-edge diagnostic products can detect the presence of the desired element even in small quantities and with a high degree of specificity, delivering reliable results that help physicians provide accurate diagnosis.

2.1. PLATFORMS

The single/low-plex solution aims at identifying the presence of infectious agents' DNA/RNA in biological samples and is composed of a thermocycler with its consumables and reagents.

Specifically, the **LIAISON® MDX** analyzer features a compact and flexible design and can be used:

- in association with the "Direct Amplification Disc (DAD)" consumable for fast, on-demand results, also at laboratories with low-volume testing, or during urgent procedures such as, for example, the identification of patients to isolate in hospitals;

- in association with the "Universal Disc (UD)" consumable for routine, screening or high-throughput results.

DAD
Direct Amplification Disc

It runs 8 specimens at a time through a pipette system for biological samples and amplification reagents, allowing the 3 steps of PCR test (extraction, amplification and detection) simultaneously on the LIAISON MDX analyzer.
The system is extremely easy to use and fast and used for fast and on demand results.



UD
Universal Disc

It runs 96 specimens simultaneously and is designed for high throughput to manage highvolume testing. It can process directly the biological samples, increasing labs throughput (96 results in an hour).

A faster and increasingly automated and compact version of this platform - the **LIAISON® MDx Plus** - is currently under development**.**

The Multiplex **VERIGENE® system** can rapidly and accurately detect a wide range of infectious pathogens and their associated drug resistance markers. The use of Multiplex technology enables clinicians to provide targeted patient care more quickly, potentially leading to improved patient outcomes, lower costs, optimized antibiotic therapy, and reduced spread of antibiotic resistance.

The VERIGENE® system is scalable, allowing throughput customization to meet the size and testing demands of each laboratory. Panels available on the VERIGENE® platform are designed to target infections in the bloodstream, respiratory tract, and gastrointestinal tract. Test cartridges are single-use and each test cartridge is designed for multiplex analysis of one patient sample.

After the VERIGENE® system the company launched the **LIAISON® Plex,** a faster and fully automated version**.** Thanks to the *Flex*™ testing concept, the new system provides full flexibility in the customization of the panel, allowing clinical laboratory staff to overcome the "one size fits all" approach for infectious disease syndromic diagnostics. This fully automated, easy to use, sample-to-answer system has a streamlined workflow with room-temperature stable consumables, allowing convenient storage and transportation. The operational hand-on time is only two minutes per sample and results are produced in less than two hours.

Lastly, the Group is developing a new molecular platform to meet the growing POC trend generated by the need for rapid and accurate tests that are performed in the close proximity of patients. The **LIAISON® NES** will provide high quality, cost effective low-plex testing, generating results in approximately 15 minutes.

3. LICENSED TECHNOLOGIES

In the field of the Licensed Technologies, Diasorin offers the market a state-of-the-art xMAP INTELLIFLEX® platform. In this sector and through Luminex, the Company sells the platform and the microspheres and provides its partners with services in the field of the in vitro diagnostic product development and in the field of applied research, using the xMAP® technology.

4. RESEARCH AND DEVELOPMENT

The diagnostic world is rapidly evolving on the back of new scientific knowledge and new therapeutic approaches.

In terms of health services, the Value Based Care approach aims to enhance prevention, optimize treatments and reduce hospital access. Diagnostics plays a key role in this approach as an accurate and rapid diagnosis improves the quality and effectiveness of treatments and reduces dispersion of resources.

To face these challenges, we need to bring our innovative potential into play and invest resources and talent to develop solutions that are capable of interpreting new trends and entering new markets.

Our growth has always been based on the consolidated ability to generate rapid and continuous innovation, meeting laboratories' needs but also introducing new diagnostic tools that enable clinicians to make the most correct decisions in the treatment of patients.

Thanks to over 400 researchers, mainly based in Italy and in the United States, and to our major investments in research and development we are able to respond to the diagnostic evolution. This is our hallmark: to bring every year cutting-edge solutions and specialty tests to laboratories all over the world, but also different and numerous applications in the clinical world and research, consolidating every day our positioning as Diagnostic Specialists.

OVERVIEW OF THE RESULTS

1. CONSOLIDATED FINANCIAL HIGHLIGHTS

Income statement *(in thousands of Euros)*	**6/30/2024**	**6/30/2023**
Net revenues	589,206	576,390
Gross profit	389,933	378,685
Adjusted (1) Gross profit	389,933	378,685
EBITDA (2)	196,371	182,374
Adjusted (1) EBITDA	198,410	189,996
EBIT	131,718	117,396
Adjusted (1) EBIT	153,159	144,429
Net profit for the period	95,504	86,859
Adjusted (1) Net profit	119,716	113,091

Statement of financial position *(in thousands of Euros)*	**6/30/2024**	**12/31/2023**
Capital invested in non-current assets	2,285,262	2,215,855
Net invested capital	2,395,976	2,314,341
Net financial debt	(781,163)	(776,373)
Shareholders' equity	1,614,813	1,537,968

Statement of cash flows *(in thousands of Euros)*	**6/30/2024**	**6/30/2023**
Net cash flow for the period	(110,744)	14,511
Free cash flow (3)	91,052	104,267
Capital expenditures	65,189	45,147
Number of employees	3,186	3,278

(1) The Adjusted Gross Profit, Adjusted EBIT, Adjusted EBITDA, and Adjusted Net Profit indicators are provided in the table included in the section "Overview of the Group's performance in the first half of 2024 and comparison with 2023".

(2) EBITDA is defined as the "Operating Result", gross of amortization and depreciation of intangible and tangible assets. EBITDA is a measure used by the Group to monitor and evaluate the Group's operating performance and is not defined as an accounting measure in IFRS and therefore shall not be considered an alternative measure for assessing the Group operating result performance. Since the composition of EBITDA is not regulated by the reference accounting standards, the criterion of determination applied by the Group may not be homogeneous with that adopted by other operators and/or groups and therefore may not be comparable

(3) Free cash flow is the cash flow from operating activities, counting utilizations for capital expenditures but before interest payments, acquisitions of companies and business operations and taking out/repaying borrowings.

2. Overview of the Group's performance in the first half of 2024 and comparison with 2023

Foreword

These Half-Year Consolidated Financial Statements at 30 June 2024 have been prepared in compliance with the International Accounting Standards (IFRS) issued by the International Accounting Standards Board ("IASB") and approved by the European Union and are consistent with the provisions issued in implementation of Art. 9 of Legislative Decree No. 38/2005.

This Half-Year Report presents and comments on alternative performance measures that are not identified in the IFRSs. These measures, which are described below, are used to comment on the Group's business performance in sections "Consolidated financial highlights" and "Review of the Group's operating performance and financial position", in compliance with the requirements of Consob communication of 28 July 2006 (DEM 6064293), as subsequently amended and supplemented (Consob communication 0092543 of 3 December 2015, which incorporates the ESMA Guidelines 2015/1415) and ESMA Guidelines 32-382-1138 of 4 March 2021.

The alternative performance measures listed below should be used to supplement the information required by IFRS to help readers of the report gain a more comprehensive understanding of the Group's economic, financial and operating position, by excluding the result of one-off elements for the Luminex integration from the amortization deriving from the Purchase Price Allocation of Luminex, the financial expenses related to the financing of the transaction, charges arising from the remeasurement (as required by IFRS 5) of the Flow Cytometry assets sold to Cytek in 2023, and the related tax impact.

It should be noted that the calculation of these Adjusted measures could differ from those used by other companies.

The following provides the alternative performance measures at 30 June 2024:

(in € thousands)	Gross Profit	EBITDA	EBIT	Net Result
IFRS Financial Statements Measures	**389,933**	**196,371**	**131,718**	**95,504**
Adjustments				
One-off costs related to the integration and restructuring of Luminex	-	2,039	2,039	2,039
Amortization of surplus values of Luminex intangibles identified in the Purchase Price Allocation	-	-	19,401	19,401
Financial charges related to the debt instruments and to convertible bond issued to finance the acquisition of Luminex net of hedging effects	-	-	-	10,003
Total adjustments before tax effect	**-**	**2,039**	**21,440**	**31,444**
Tax effect on adjustments	-	-	-	(7,232)
Total adjustments	**-**	**2,039**	**21,440**	**24,212**
Adjusted Measures	**389,933**	**198,410**	**153,159**	**119,716**

The following provides the alternative performance measures at 30 June 2023:

(in € thousands)	Gross Profit	EBITDA	EBIT	Net Result
IFRS Financial Statements Measures	**378,685**	**182,374**	**117,396**	**86,859**
Adjustments				
One-off costs related to the integration and restructuring of Luminex	-	7,621	7,621	7,621
Amortization of surplus values of Luminex intangibles identified in the Purchase Price Allocation	-	-	19,412	19,412
Financial charges related to the debt instruments and to convertible bond issued to finance the acquisition of Luminex net of hedging effects	-	-	-	7,035
Total adjustments before tax effect	**-**	**7,621**	**27,033**	**34,068**
Tax effect on adjustments				(7,836)
Total adjustments	**-**	**7,621**	**27,033**	**26,232**
Adjusted Measures	**378,685**	**189,996**	**144,429**	**113,091**

Macroeconomic scenario and the foreign exchange market

The first half of 2024 showed a modest slowdown in global inflation that may lead to an expected and progressive monetary policy easing by major central banks, marking the start of a new cycle of interest-rate cuts.

The macroeconomic scenario for the second half of 2024 is still uncertain: inflation rates and the international geopolitical instability continue to affect global growth which is expected to be slightly above 3% in 2024, basically unchanged compared to the previous year (source: OECD).

In the foreign exchange market, the US Dollar appreciated against the Euro from the end of 2023, even though it remained stable as compared with the average of the first half of 2023.
It should be noted that among the main reference currencies used by the Group, in terms of H1 average exchange rates, the Chinese Yuan depreciated 4 percentage points and the Brazilian real was down 10 percentage points compared to the end of 2023.

The following table provides a comparison of the average and end-of-period exchange rates (source: European Central Bank) concerning the Group's main currencies in the first half of 2024 and 2023.

Currency	Average exchange rates		Exchange rates at	Average exchange rates		
	2024	2023	Change	6/30/2024	12/31/2023	Change
U.S. dollar	1.0813	1.0807	0%	1.0705	1.1050	-3%
Brazilian real	5.4922	5.4827	0%	5.8915	5.3618	10%
British pound	0.8546	0.8764	-2%	0.8464	0.8691	-3%
Swedish kronor	11.3914	11.3329	1%	11.3595	11.0960	2%
Swiss franc	0.9615	0.9856	-2%	0.9634	0.9260	4%
Czech koruna	25.0149	23.6873	6%	25.0250	24.7240	1%
Canadian dollar	1.4685	1.4565	1%	1.4670	1.4642	0%
Mexican peso	18.5089	19.6457	-6%	19.5654	18.7231	4%
Israeli shekel	3.9951	3.8828	3%	4.0200	3.9993	1%
Chinese yuan	7.8011	7.4894	4%	7.7748	7.8509	-1%
Australian dollar	1.6422	1.5989	3%	1.6079	1.6263	-1%
South African rand	20.2476	19.6792	3%	19.4970	20.3477	-4%
Norwegian krone	11.4926	11.3195	2%	11.3965	11.2405	1%
Polish zloty	4.3169	4.6244	-7%	4.3090	4.3395	-1%
Indian Rupee	89.9862	88.8443	1%	89.2495	91.9045	-3%
Singapore dollar	1.4561	1.4440	1%	1.4513	1.4591	-1%
UAE Dirham	3.9709	3.9687	0%	3.9314	4.0581	-3%

3. REVIEW OF THE GROUP'S OPERATING PERFORMANCE AND FINANCIAL POSITION

Foreword

The accounting standards applied to prepare these Half-Year Consolidated Financial Statements are consistent with those used for the Annual Consolidated Financial Statements at 31 December 2023, except as otherwise stated in the Notes to the Financial Statements– paragraph "New accounting standards".

Operating performance in the first half of 2024 and comparison with 2023

(in thousands of Euros)	**6/30/2024**	**As a % of revenues**	**6/30/2023**	**As a % of revenues**
Net revenues	589,206	100.0%	576,390	100.0%
Cost of sales	(199,273)	33.8%	(197,705)	34.3%
Gross profit	**389,933**	**66.2%**	**378,685**	**65.7%**
Sales and marketing expenses	(141,224)	24.0%	(141,934)	24.6%
Research and development costs	(43,233)	7.3%	(46,355)	8.0%
General and administrative expenses	(64,141)	10.9%	(61,400)	10.7%
Total operating expenses	**(248,598)**	**42.2%**	**(249,688)**	**43.3%**
Other operating income (expense)	(9,617)	1.6%	(11,602)	2.0%
EBIT	**131,718**	**22.4%**	**117,396**	**20.4%**
Adjusted EBIT	**153,159**	**26.0%**	**144,429**	**25.1%**
Financial income	6,462	1.1%	10,680	1.9%
Financial expense	(14,148)	2.4%	(15,272)	2.6%
Profit before taxes	**124,033**	**21.1%**	**112,804**	**19.6%**
Income taxes	(28,528)	4.8%	(25,945)	4.5%
Net profit for the period	**95,504**	**16.2%**	**86,859**	**15.1%**
Adjusted net profit for the period	**119,716**	**20.3%**	**113,091**	**19.6%**
EBITDA (1)	**196,371**	**33.3%**	**182,374**	**31.6%**
Adjusted EBITDA	**198,410**	**33.7%**	**189,996**	**33.0%**

(1) Looking at the data on the Table, the Board of Directors defines EBITDA as the "operating result" before amortization of intangibles and depreciation of property, plant and equipment. EBITDA is a measure used by the Company to monitor and evaluate the Group's operating performance and is not defined as an accounting measure in IFRS and therefore shall not be considered an alternative measure for assessing the Group's operating result performance. Since the composition of EBITDA is not regulated by the reference accounting standards, the criterion of determination applied by the Group may not be homogeneous with that adopted by other operators and/or groups and therefore it may not be comparable.

Net revenues

In the first half of 2024, Diasorin generated **revenues for € 589,206 thousand** (€ 576,390 thousand in the first half of 2023) up by 2.2% compared to the first half of 2023 (2.3% at CER). At constant perimeter of consolidation, therefore neutralizing the effects of the sale of Flow Cytometry business (divested in February 2023) and excluding the COVID business, revenues increased by 7.0% (+7.1% at CER). At constant perimeter of consolidation and net of COVID business, the second quarter reported a faster growth, with revenue growth equal to 7.9% (+7.5% at CER). The increase is mostly attributable to the excellent performance of the immunodiagnostic and molecular diagnostic businesses, driven by the specialty menu and innovative solutions for the market of laboratories.

Revenues by technology

(in thousands of Euros)	**2024**	**% of revenues 2024**	**2023**	**% of revenues 2023**
Ex-COVID immunodiagnostics	390,726	66.3%	355,127	61.7%
Ex-COVID molecular diagnostics	100,494	17.1%	97,019	16.8%
Licensed Technologies	83,885	14.2%	89,587	15.5%
COVID	14,101	2.4%	34.658	6.0%
Total	**589,206**	**100.0%**	**576,390**	**100.0%**

Ex-COVID immunodiagnostic revenues were € 390,726 thousand and increased by 10.0% (+10.2% at CER). In the second quarter of 2024, the business grew by +11.7% (+11.5% at CER), accelerating when compared to Q1 2024, mainly on the back of the excellent performance of the U.S. market driven by the Hospital Strategy and the broad offer of specialties, and the European market due to increased volumes in most countries in the region.

Ex-COVID molecular diagnostic revenues were € 100,494 thousand, up by 3.6% compared to the first half of 2023 (unchanged at CER), on the back of the positive sales trend of respiratory panels (+12.7% both at current exchange rates and at CER), only partly offset by loss of a major contract for cystic fibrosis testing occurred in 2023. In the second quarter of 2024, the business grew by +6.3% (+5.3% at CER), accelerating compared to the first quarter of 2024, mainly due to the legacy Diasorin molecular business, the respiratory business, and the resilience of the multiplexing business on the Verigene platform. Q2 2024 revenues do not yet incorporate the contribution of LIAISON PLEX® (launched onto the market in June). Net of the negative impact of the cystic fibrosis business, growth for the second quarter would have been even more significant and equal to +8.4% at CER.

Licensed Technologies revenues were € 83,885 thousand. The decrease of 6.4% over the first half of 2023 (-6.2% at CER) is mostly due to the sale of the Flow Cytometry business divested in February 2023. At constant perimeter of consolidation, revenues show a slight decrease of -1.9% (-1.7% at CER).

Sales of COVID serology and molecular diagnostic tests were in line with expectations and equal to € 14,101 thousand, down by € 20,557 thousand compared to the first half of 2023.

Breakdown of Revenues by geography

The following table provides a comparison of revenues in the periods under comparison, broken down by geographic areas.

(in thousands of Euros)	**2024**	**2023**	**% Change at current exchange rates**	**% Change at constant exchange rates**
Europe direct	206,976	191,928	7.8%	7.5%
North America direct	279,084	255,044	9.4%	9.5%
Rest of the World	89,045	94,761	-6.0%	-4.9%
COVID	14,101	34,658	-59.3%	-59.3%
Total Revenues	**589,206**	**576,390**	**2.2%**	**2.3%**





Europe Direct

Revenues in the first half of 2024 were € 206,976 thousand, up 7.8% (+7.5% at CER) compared to 2023. The growth was driven by the positive performance of the Immunodiagnostic business, with a focus on the specialty tests that characterize Diasorin's offerings.

In the second quarter of 2024, the immunodiagnostic business (+11.8% at CER) and molecular diagnostic business (+9.8% at CER) show an acceleration over the previous quarter, as a result of increased sales volumes in most countries of this area.

North America Direct

Revenues in the first half of 2024 were € 279,084 thousand, up 9.4% (+9.5% at CER) compared to 2023.

The growth was driven by the excellent performance of the immunodiagnostic business, as a result of the success of the Hospital Strategy and the broad offering of specialties, as well as a sound performance of the molecular diagnostic business, despite not yet incorporating the contribution of LIAISON PLEX® (launched onto the market in June).

The second quarter of 2024 reported an acceleration of both the immunodiagnostic business (over +22.1% at CER) and the molecular diagnostic business (+6.2% at CER) compared to the same period of the previous year.

Rest of the World

Revenues in the first half of 2024 were € 89,045 thousand, down 6.0% (-4.9% at CER) compared to 2023. The trend in this geographic area was negatively impacted by the performance of markets where Diasorin operates through distributors and by the Chinese market's performance, partially offset by the positive trend of markets where the Group operates directly through its commercial branches.

Operating performance

The gross profit in the first half of 2024 was € 389,933 thousand, up by € 11,248 thousand compared to the same period of 2023 (+3%), equal to 66.2% of revenues as against 65.7% in 2023.

Operating expenses, net of amortization deriving from the Purchase Price Allocation of Luminex amounted to € 229,197 thousand, down 1.1% compared to the same period of 2023; their ratio to total revenues was equal to 38.9% from 40.0% in 2023.

Adjusted EBITDA amounted to € **198,410 thousand**, up by 4.4% compared to the same period of 2023, and equal to 33.7% of revenues (33.0% in 2023). In the second quarter of 2024 the growth showed a sharp acceleration to +9.8% compared to 2023, with EBITDA margin at 33.8%.

EBITDA amounted to € 196,371 thousand, up by 7.7% compared to the first half of 2023, and equal to 33.3% of revenues in 2024 from 31.6% in 2023.

Adjusted EBIT amounted **to € 153,159 thousand** (€ 144,429 thousand in the first half of 2023), up by 6.0% compared to the same period of the previous year, equal to 26.0% of revenues as against 25.1% in 2023. The second quarter of 2024 contributed to the growth, which results in +13.8% over the same period of 2023.

In the first half of 2024, EBIT was € 131,718 thousand, up by 12.2% compared to the same period of 2023 and equal to 22.4% of revenues.

Financial income and expense

In the first half of 2024, net financial expenses amounted to € 7,686 thousand, as against € 4,592 thousand in the same period of 2023, up from the first half of 2023 as a result of the fair value measurement of interest rate hedging financial instruments in relation to the loan taken out in 2021 for the acquisition of Luminex.

Profit before taxes and net profit

The first half of 2024 ended with a result before taxes of € 124.033 thousand, up by 10% compared to € 112,804 thousand in the first half of 2023 and equal to 21.1% revenues. The change is due to the combined effects described above.

In the first half of 2024, **the adjusted net profit,** equal to **€ 119,716 thousand**, increased by € 6,625 thousand or 5.9% versus the first half of 2023, equal to 20.3% of revenues (19.6% in 2023).

The net profit was € 95,504 thousand (up by 10% versus the first half of 2023).

4. STATEMENT OF FINANCIAL POSITION AT 30 JUNE 2024

The consolidated statement of financial position at 30 June 2024 is provided below:

(in thousands of Euros)	**6/30/2024**	**12/31/2023**
Goodwill and Intangible assets	1,985,236	1,924,970
Property, plant and equipment	265,697	256,286
Other non-current assets	34,329	34,599
Net working capital	385,536	368,834
Other non-current liabilities	(274,822)	(270,349)
Net invested capital	**2,395,976**	**2,314,341**
Net financial debt	**(781,163)**	**(776,373)**
Total shareholders' equity	**1,614,813**	**1,537,968**

Non-current assets were € 2,285,262 thousand at 30 June 2024, up from 31 December 2023 (€ 2,215,855 thousand). The change is due to the conversion in euros of fixed assets denominated in U.S. dollar.

Amortization and depreciation, equal to € 64,651 thousand, partly offset investments amounting to € 72,924 thousand. Investments include the LIAISON PLEX and LIAISON NES projects and the completion of the manufacturing facility in China.

Other non-current liabilities were € 274,822 thousand, increasing by € 4,473 thousand compared to 31 December 2023. The increase is due to changes in exchange rates, with an impact on the amount of deferred taxes recorded by the U.S. companies.

The table that follows shows the net working capital:

(in thousands of Euros)	**6/30/2024**	**12/31/2023**
Trade receivables	195,396	198,560
Ending inventories	327,714	315,500
Trade payables	(98,667)	(100,706)
Other current assets/liabilities	(38,907)	(44,520)
Net working capital	**385,536**	**368,834**

At 30 June 2024, the net working capital was € 385,536 thousand, with an increase of € 16,702 thousand compared to the previous year.

Trade receivables amounted to € 195,396 thousand, with a slight decrease compared to December 2023.

Ending inventories were € 327,714 thousand, with an increase of € 12,214 thousand (+4%), mainly driven by materials for manufacturing Luminex instruments and reagents for new commercial launches.

Trade payables were € 98,667 thousand at 30 June 2024, down by € 2,039 thousand compared to the previous year.

Other net current liabilities were € 38,907 thousand, down by € 5,613 thousand compared to the previous year; mainly as a result of variable fees paid to employees and related payables to social security institutions.

The **net financial debt** at 30 June 2024 was **negative by € 781,163 thousand.**

The table that follows shows the consolidated net financial debt:

	(in thousands of Euros)	**6/30/2024**	**12/31/2023**	**Change**
A	Cash on hand	169,570	280,314	(110,744)
B	Cash equivalents	-	-	-
C	Other current financial assets	47,298	98,437	(51,139)
D	**Cash (A+B+C)**	**216,868**	**378,751**	**(161,883)**
E	Current financial debt (including debt instruments, but excluding the current portion of non-current financial borrowings)	59,609	63,346	(3,737)
F	Current portion of non-current financial borrowing	-	21,728	(21,728)
G	**Current financial debt (E+F)**	**59,609**	**85,074**	**(25,465)**
H	**Net current financial debt (G-D)**	**(157,259)**	**(293,677)**	**136,418**
I	Non-current financial debt (excluding the current portion and debt instruments)	475,952	612,254	(136,301)
J	Debt instruments	462,471	457,797	4,674
K	Trade payables and other non-current borrowings	-	-	-
L	**Non-current financial debt (I+J+K)**	**938,423**	**1,070,050**	**(131,626)**
M	**Total financial debt (H+L)**	**781,163**	**776,373**	**4,790**

As regards the net financial debt of the period, the following is detailed:

- Repayment of a principal of USD 50,000,000 in January and of USD 125,000,000 in April concerning the “Term Loan”, in addition to € 5,682 thousand in interest expense.
- Use of additional € 39,867 thousand concerning the “Revolving Credit Facility”.
- Opening and use of a credit line by the Chinese subsidiary, for an amount equal to € 11,647 thousand.
- Use of liquidity held by Diasorin Inc. in Time Deposit instruments, for an amount equal to € 47,298 thousand, down from € 50,855 thousand at 31 December 2023.

Further details on the debt instruments above are provided in the Notes to the financial statements.

At 30 June 2024, the **consolidated shareholders' equity** was **€ 1,614,813 thousand** (€ 1,537,968 thousand at 31 December 2023) and includes no. 2,632,381 treasury shares, equal to 4.71% of the share capital, for a total value of € 301,338 thousand.

Analysis of consolidated cash flows

A complete statement of consolidated cash flows is provided in the financial statements. A schedule showing a condensed consolidated statement of cash flows, followed by a review of the main statement items and changes that occurred compared to the previous year is provided below.

(in thousands of Euros)	**1st half 2024**	**1st half 2023**
Cash and cash equivalents- Opening balance	**280,314**	**241,776**
Net cash from operating activities	154,916	145,643
Cash used for investing activities	(10,965)	107,777
Cash used from/(for) financing activities	(254,695)	(238,910)
Change in net cash before investments in financial assets	***(110,744)***	***14,511***
Investments in financial assets	-	-
Change in net cash	***(110,744)***	***14,511***
Cash and cash equivalents – Closing balance	**169,570**	**256,287**

At 30 June 2024, available **liquid assets** held by the Group amounted to **€ 169,570 thousand**, a decrease of € 86,716 million compared to the first half of 2023.

In the first half of 2024, the cash flow from operating activities was € 154,916 thousand, up by € 9,273 thousand compared to the same period of 2023, mainly due to the increase in EBITDA, as described above.

Investing activities absorbed cash for € 10,965 thousand; the change of € 118,742 thousand compared to the first half of 2023 is mainly attributable to increased disposals, in 2023, of time deposit instruments used by U.S. companies for cash denominated in U.S. dollars and to the proceeds from sale of the Flow Cytometry business in 2023. It should be noted in the first half of 2024 increased investing activities in new technologies and in products that will be soon launched.

The **free cash flow** in the first half of 2024 amounted to **€ 91,052 thousand**, down by € 13,215 thousand as against € **104,267** thousand in the first half of 2023, as a result of increased investments in research and development activities described above. Net cash from financing activities amounted to € 254,695 thousand, as against € 238,910 thousand generated in the first half of 2023. This cash outlay is the result of the Term Loan repayments described above, partly offset by the use of the Revolving Credit Facility. Dividend distribution amounted to € 61,277 thousand (€ 58,606 thousand in 2023) and the purchase of treasury shares, net of stock options exercise, amounted to € 7,329 thousand (€ 22,952 thousand in 2023).

5. TRANSACTIONS RESULTING FROM NON-RECURRING, ATYPICAL AND/OR UNUSUAL OPERATIONS

Consistent with Consob Communication No. DEM/6064293 of 28 July 2006, in 2024 the Group did not carry out atypical and/or unusual transactions, as provided by the Communication which defines as atypical and/or unusual transactions those transactions that, because of their significance/materiality, type of counterparty, purpose, method used to determine the transfer price and timing (close to the end of the year), could give rise to doubts with regard to: the accuracy/completeness of the disclosure provided in the financial statements, conflict of interests, safety of the corporate assets and protection of non-controlling shareholders.

6. MAIN RISKS AND UNCERTAINTIES TO WHICH THE GROUP IS EXPOSED

Risks connected to general economic condition

The Group's economic, financial and operating position is unavoidably affected by macroeconomic and macropolitical factors beyond the Company's control.

The products distributed by Diasorin are part of basic medical care coverage which, generally, is funded by national health services or private insurance companies. Some countries where the Group operates may question costs of welfare system, in which health care has a central role. This phenomenon can lead to increase pressure to reduce refunds for medical care and, in some cases, the volumes of laboratory tests ordered by physicians.

This may have an impact on the market where Diasorin operates, despite diagnostics accounts for only a marginal portion of health care spending in the main industrialized countries and its use may help national health services curb costs in terms of treatments and hospitalizations.

It should also be noted that despite its downward trend, the inflationary pressure may lead to an increase in the cost base resulting in lower margins that Diasorin could not face with a corresponding increase in prices applied to customers. To date, this phenomenon has no material impact on the Group's figures.

Risks related to the Group's international presence and expansion

Because of their presence in several emerging markets, the Company and the Group are exposed to numerous risk factors. The current economic and macropolitical situation, which is negatively impacted by Ukraine and Middle East crises, exposes some of these countries to social, economic and political instability, thus jeopardizing growth in such countries. Nevertheless, the Group is not significantly exposed in these markets.

In countries where it does not operate through a subsidiary, the Group uses independent distributors to sell its products. As a rule, these distributors are small or medium-sized companies with limited financial resources, whose risk could be to slow sales growth or increase the risk that a distributor may become insolvent.

Risks related to funding requirements

A prudent cash management strategy includes maintaining sufficient cash or readily available assets and credit lines to meet immediate liquidity needs. Cash flows, the need for financing and liquidity are monitored and managed centrally, in order to promptly guarantee an effective raising of the financial resources or an adequate employment of the liquidity available.

In order to meet any financial needs and a credit market characterized by low liquidity, the Company has deemed it appropriate to adopt a EUR 150 million 3 year committed revolving credit facility, to be used upon set conditions.

Management believes that the funds and credit lines currently available, when combined with the resources generated by operating and financing activities (including dividends from subsidiaries), will enable the Group to meet its liquidity needs.

Credit risk

In certain emerging countries, receivables owed to the Company and to the Group can be affected by the limited financial liquidity of local customers and therefore the collection terms may be significantly longer than the contractual payment terms.

Impairment losses on receivables are recognized through the simplified approach required by IFRS 9 to measure loss allowance through lifetime expected credit loss. Specifically, the Group calculates expected credit loss using a provision matrix which is estimated on the basis of historical credit loss experience for past due receivables and is adjusted to reflect current conditions and estimates on relevant future economic conditions.

Risks associated with foreign exchange and interest rate fluctuations

The Group operates in countries and markets where the reporting currency is not the Euro and, consequently, it is exposed to the risk related to fluctuation in foreign exchange rates.

With regard to revenues, the currencies to which DiaSorin is increasingly exposed are the U.S. Dollar (accounting for about 50% of revenues in 2024), the Chinese Yuan (accounting for about 4% of revenues in 2024) and the Canadian Dollar (accounting for about 3% of revenues in 2024).

With regard to the company's financial position, a significant portion of the debt from Luminex acquisition is denominated in U.S. Dollar (accounting for about 45% of the Group's financial liabilities at 30 June 2024), consistently with the currency of the assets acquired and with the economic composition of revenues.

Future fluctuations of the Euro versus other currencies may have an impact, even though marginal, on the economic, financial and operating position of the Company and of the Group.

With regard to interest rates, it should be noted that:

- floating-rate interest, as contractually defined, accrues on the debt denominated in U.S. dollars of the subsidiary DiaSorin Inc. for the Luminex acquisition. The company used Interest Rate Swaps as a hedge against potential negative impacts deriving from any rise in interest rates;
- interest expense does not accrue on the convertible bond issued by the Group's Parent Company.

Therefore, the Group is not significantly exposed to risks associated with interest rate fluctuations as it has proper hedging instruments.

Commercial risk

Diasorin operates in a market characterized by major competitors that use particularly aggressive strategies and exert pressure on sales price. This applies to high-volume products, the so-called mainstream products, that are present in all major competitors' menus. In order to limit this phenomenon, the Group developed a strong specialty menu to enter niche markets. Furthermore, following the trend recorded in countries where small lab chains merged into big chains, revenues may be concentrated at some major customers. Potential risks connected to this phenomenon are mitigated through the adoption of long-term contracts and the implementation of a commercial strategy aimed at expanding the customer base that is composed of medium and small-sized hospital laboratories.

7. SIGNIFICANT EVENTS OCCURRED AFTER 30 JUNE 2024 AND BUSINESS OUTLOOK

With regard to the evolution of litigation on the application of medical device payback regulation in Italy, it should be noted that on 22 July 2024, the Constitutional Court issued rulings no. 139 and no. 140. Specifically, by ruling no. 140, on a referral from the Regional Administrative Court ("TAR") of Lazio, the Court stated that issues concerning the constitutional legitimacy in relation to art. 9-ter of the Law Decree 78/2015 for the years 2015-2018 were unfounded, as the Court considered the measure a solidarity contribution which is correlated to reasons of social utility. The Court specified that, in relation to this period, the lawmaker introduced a specific regulation for the amount in excess of the spending cap and the Regions, by adopting their own measures, required companies the payments of the amounts due. The Court also established all companies are unconditionally entitled to reduce their payment to 48% of the original amount due, without excluding those companies that did not waive their right to appeal against the payback measures.

As required by the administrative process, the appeals filed will continue at the Regional Administrative Court for the examination of further objections raised by the supplier companies involved.

In the light of the above, the Management believes that the accounting estimates used for the preparation of the Half-Year Condensed Consolidated Financial Statements at 30 June 2024 are reasonable.

Lastly, as regards business outlook, the Management revised full-year 2024 guidance at 2023 CER:

- EX COVID REVENUES: between *+6%* and *+7%* (COVID revenues equal to € 30 million)
- ADJUSTED EBITDA MARGIN: approx. *33%*

8. RELATED-PARTY TRANSACTIONS

Diasorin S.p.A. has engaged on a regular basis in commercial and financial transactions with its subsidiaries, which are also Group companies. These transactions, which are executed on standard market terms, consist of the supply of goods and services, including administrative, information technology, personnel management, technical support and consulting services, which produce receivables and payables at the end of the year, and financing and cash management transactions, which produce income and expenses. The impact of these transactions on the single items of the statement of financial position, the income statement and the cash flow is summarized in the financial statements and detailed in Note 30 of the Half-Year Condensed Consolidated Financial Statements

HALF-YEAR CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AT 30 JUNE 2024

1. CONSOLIDATED INCOME STATEMENT

(in thousands of Euros)	**Notes**	**1st half 2024**	***amount with related parties***	**1st half 2023**	***amount with related parties***
Net revenues	(1)	589,206		576,390	
Cost of sales	(2)	(199,273)		(197,705)	
Gross profit		**389,933**		**378,685**	
Sales and marketing expenses	(3)	(141,224)		(141,934)	
Research and development costs	(4)	(43,233)		(46,355)	
General and administrative expenses	(5)	(64,141)	(3,278)	(61,400)	(3,818)
Other operating income (expense)	(6)	(9,617)		(11,602)	
non-recurring amount		*(2,181)*		*(8,388)*	
EBIT		**131,718**		**117,396**	
Financial income	(7)	6,462		10,680	
Financial expense	(8)	(14,148)		(15,272)	
Profit before taxes		**124,033**		**112,804**	
Income taxes	(9)	(28,528)		(25,945)	
Net profit		**95,504**		**86,859**	
Of which:					
- attributable to equity holders of the Parent		96,006		88,118	
- attributable to non-controlling interests		(502)		(1,259)	
Earnings per share (basic)	(10)	**1.71**		**1.55**	
Earnings per share (diluted)	(10)	**1.71**		**1.55**	

2. CONSOLIDATED COMPREHENSIVE INCOME STATEMENT

(in thousands of Euros)	Notes	1st half 2024	1st half 2023
Net profit for the period (A)		**95,504**	**86,859**
Other comprehensive gains/(losses) that will not be reclassified subsequently to gain/(loss) of the period:			
Gains/(losses) on remeasurement of defined benefit plans	(22)	21	(286)
Total other comprehensive gains/(losses) that will not be reclassified subsequently to gain/(loss) of the period (B1):		**21**	**(286)**
Other comprehensive gains/(losses) that will be reclassified subsequently to gain/loss of the period:			
Gains/(losses) from translation of financial statements of foreign branches	(20)	49,654	(26,870)
Gains/(losses) on cash flow hedges	(20)	(5,025)	(6,239)
Total other comprehensive gains/(losses) that will be reclassified subsequently to gain/(loss) of the period (B2)		**44,629**	**(33,109)**
TOTAL OTHER COMPREHENSIVE GAINS/(LOSSES), NET OF TAX EFFECT (B1) +(B2) =(B)		**44,650**	**(33,395)**
TOTAL COMPREHENSIVE GAIN/(LOSS) (A)+(B)		**140,154**	**53,464**
Of which:			
- attributable to equity holders of the Parent		140,688	54,668
- attributable to non-controlling interests		(534)	(1,204)

3. CONSOLIDATED STATEMENT OF FINANCIAL POSITION

(in thousands of Euros)	**notes**	**6/30/2024**	***amount with related parties***	**12/31/2023**	***amount with related parties***
ASSETS					
Non-current assets					
Property, plant and equipment	(11)	265,697		256,286	
Goodwill	(12)	823,412		799,365	
Intangible assets	(12)	1,161,824		1,125,605	
Equity investments	(13)	26		26	
Deferred-tax assets	(14)	31,310		31,813	
Other non-current assets	(15)	2,993		2,760	
Other non-current financial assets	(21)	9,381		12,891	
Total non-current assets		*2,294,643*		*2,228,747*	
Current assets					
Inventories	(16)	327,714		315,500	
Trade receivables	(17)	195,396		198,560	
Other current assets	(18)	69,187		65,243	
Other current financial assets	(21)	69,003		123,075	
Cash and cash equivalents	(19)	169,570		280,314	
Total current assets		*830,870*		*982,692*	
TOTAL ASSETS		**3,125,513**		**3,211,439**	

CONSOLIDATED STATEMENT OF FINANCIAL POSITION *(continued)*

(in thousands of Euros)	**notes**	**6/30/2024**	***amount with related parties***	**12/31/2023**	***amount with related parties***
LIABILITIES AND SHAREHOLDERS' EQUITY					
Shareholders' equity					
Share capital	(20)	55,948		55,948	
Treasury shares	(20)	(301,338)		(296,797)	
Additional paid-in capital	(20)	18,155		18,155	
Statutory reserve	(20)	11,190		11,190	
Other reserves and retained earnings	(20)	1,736,029		1,590,266	
Net profit for the period		96,006		159,849	
Total Group's consolidated shareholders' equity		*1,615,990*		*1,538,611*	
Other reserves and retained earnings attributable to non-controlling interests		(643)		761	
Net profit attributable to non-controlling interests		(534)		(1,404)	
Shareholders' equity attributable to non-controlling interests		*(1,177)*		*(643)*	
Total Consolidated Shareholders' Equity		**1,614,813**		**1,537,968**	
Non-current liabilities					
Non-current financial liabilities	(21)	969,509		1,083,005	
Provisions for employee benefits	(22)	32,324	-	32,314	-
Deferred-tax liabilities	(14)	204,789		199,596	
Provisions for risks and charges	(23)	27,031		27,700	
Other non-current liabilities	(24)	10,677		10,740	
Total non-current liabilities		*1,244,331*		*1,353,354*	
Current liabilities					
Trade payables	(25)	98,667		100,706	
Other current liabilities	(26)	87,571	-	100,364	82
Current tax liabilities	(27)	20,523		9,399	
Current financial liabilities	(21)	59,609		109,649	
Total current liabilities		*266,370*		*320,117*	
Total liabilities		**1,510,701**		**1,673,471**	
TOTAL SHAREHOLDERS' EQUITY AND LIABILITIES		**3,125,513**		**3,211,439**	

4. CONSOLIDATED STATEMENT OF CASH FLOWS

(in thousands of Euros)	**Notes**	**1st half 2024**	***amount with related parties***	**1st half 2023**	***amount with related parties***
Cash flow from operating activities					
Net profit for the year		95,504		86,859	
Adjustments for:					
- Income taxes	(9)	28,528		25,945	
- Depreciation and amortization	(11) (12)	64,651		64,992	
- Financial expense (income)	(7) (8)	7,686		4,592	
- Additions to/(Utilizations) of provisions for risks	(23)	(840)		(2,595)	
- (Gains)/Losses on sales of non-current assets	(6)	126		516	
- Additions to/ (Reversals of) provisions for employee severance indemnities and other benefits	(22)	(90)		45	
- Stock options reserve	(20)	5,297		2,584	
- Translation reserve on operating activities	(20)	(25,095)		12,031	
- Change in other non-current assets/liabilities	(15) (24)	13,323	-	(12,207)	(7,952)
Cash flow from operating activities before changes in working capital		189,090		**182,762**	
(Increase)/Decrease in current receivables	(17)	5,462		32,227	
(Increase)/Decrease in inventories	(16)	(6,528)		(19,364)	
Increase/(Decrease) in trade payables	(25)	(841)		1,836	
(Increase)/Decrease in other current items	(18) (26)	(19,391)	(82)	(38,387)	
Cash from operating activities		**167,793**		**159,075**	
Income taxes paid	(9) (27)	(12,384)		(9,661)	
Collected interests / (paid)	(21)	(493)		(3,772)	
Net cash from operating activities		**154,916**		**145,643**	
Investments in intangible assets	(12)	(40,214)		(29,021)	
Investments in property, plant and equipment	(11)	(24,975)		(18,146)	
Disposals of intangible assets and property, plant and equipment	(11) (12)	832		2,020	
(Opening)/Repayment of term deposit	(21)	53,392		114,488	
Cash flow from sale of the Flow Cytometry business		-		38,436	
Cash used by regular investing activities		**(10,965)**		**107,777**	
(Repayment of)/ Proceeds from loans and other financial liabilities	(21)	(192,038)		(153,220)	
(Purchase)/Sale of treasury shares	(20)	(7,343)		(22,952)	
Dividend distribution	(20)	(61,277)		(58,606)	
Cash used by financing activities		**(260,658)**		**(234,778)**	
Currency translation effect		5,963		(4,132)	
Net change in cash		**(110,744)**		**14,511**	
Cash and cash equivalents- Opening balance		**280,314**		**241,776**	
Cash and cash equivalents - Closing balance		**169,570**		**256,287**	

5. STATEMENT OF CHANGES IN CONSOLIDATED SHAREHOLDERS' EQUITY

(in thousands of Euros)	Share capital	Treasury shares	Additional paid-in capital	Statutory reserve	Translation reserve	Stock option reserve	Reserve for treasury shares	Other reserves and retained earnings	Net profit for the year	Group's interest in shareholders' equity	Non-controlling interest in shareholders' equity	Total interest in shareholders' equity
Shareholders' equity at 12/31/2022	**55,948**	**(281,277)**	**18,155**	**11,190**	**121,000**	**25,444**	**281,277**	**1,046,346**	**240,907**	**1,518,990**	**761**	**1,519,750**
Allocation of previous year's profit	-	-	-	-	-	-	-	240,907	(240,907)	**-**	-	**-**
Dividend distribution	-	-	-	-	-	-	-	(58,870)	-	**(58,870)**	-	**(58,870)**
Stock options and other changes	-	-	-	-	-	2,491	-	93	-	**2,584**	-	**2,584**
Sale/(Purchase) of treasury shares	-	(21,348)	-	-	-	-	21,348	(21,276)	-	**(21,276)**	-	**(21,276)**
Put/Call option rights on subsidiaries	-	-	-	-	-	-	-	(13)	-	**(13)**	13	**-**
Profit for the year	-	-	-	-	-	-	-	-	*88,118*	***88,118***	*(1,259)*	***86,859***
Gains/(losses) on remeasurement of defined benefit plans, net of tax effect	-	-	-	-	-	-	-	(286)	-	**(286)**	-	**(286)**
Translation adjustments	-	-	-	-	(26,870)	-	-	-	-	**(26,870)**	-	**(26,870)**
Cash flow hedge reserve	-	-	-	-	-	-	-	(6,239)	-	**(6,239)**	-	**(6,239)**
Other changes in the comprehensive income statement	-	-	-	-	*(26,870)*	-	-	*(6,525)*	-	***(33,395)***	-	***(33,395)***
Comprehensive profit	-	-	-	-	(26,870)	-	-	(6,525)	88,118	**54,723**	(1,259)	**53,464**
Shareholders' equity at 6/30/2023	**55,948**	**(302,625)**	**18,155**	**11,190**	**94,130**	**27,935**	**302,625**	**1,200,663**	**88,118**	**1,496,138**	**(485)**	**1,495,653**

Shareholders' equity at 12/31/2023	**55,948**	**(296,797)**	**18,155**	**11,190**	**67,572**	**32,240**	**296,797**	**1,193,657**	**159,849**	**1,538,611**	**(643)**	**1,537,968**
Allocation of previous year's profit	-	-	-	-	-	-	-	159,849	(159,849)	**-**	-	**-**
Dividend distribution	-	-	-	-	-	-	-	(61,277)	-	**(61,277)**	-	**(61,277)**
Stock options and other changes	-	-	-	-	-	4,651	-	646	-	**5,297**	-	**5,297**
Sale/(Purchase) of treasury shares	-	(4,541)	-	-	-	-	4,541	(7,329)		**(7,329)**	-	**(7,329)**
Put/Call option rights on subsidiaries	-	-	-	-	-	-	-	-	-	**-**		**-**
Profit for the year	-	-	-	-	-	-	-	-	*96,006*	**96,006**	*(502)*	***95,504***
Gains/(losses) on remeasurement of defined benefit plans, net of tax effect	-	-	-	-	-	-	-	21	-	**21**	-	**21**
Translation adjustments	-	-	-	-	49,686	-	-	-	-	**49,686**	(32)	**49,654**
Cash flow hedge reserve	-	-	-	-	-	-	-	(5,025)	-	**(5,025)**	-	**(5,025)**
Other changes in the comprehensive income statement	-	-	-	-	*49,686*	-	-	*(5,004)*	-	**44,682**	*(32)*	***44,650***
Comprehensive profit	-	-	-	-	49,686	-	-	(5,004)	96,006	140,688	(534)	140,154
Shareholders' equity at 6/30/2024	**55,948**	**(301,338)**	**18,155**	**11,190**	**117,258**	**36,891**	**301,338**	**1,280,542**	**96,006**	**1,615,990**	**(1,177)**	**1,614,813**

6. NOTES TO THE HALF-YEAR CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

General information and scope of consolidation

General information

The Diasorin Group is specialized in the development, manufacturing and marketing of immunodiagnostic and molecular diagnostic tests and Life Science solutions, which include the *xMAP*® microsphere-based technology, sold for the development of kits or for use in the field of research and development.

The Group's Parent Company, Diasorin S.p.A., is in Via Crescentino (no building No.), Saluggia (VC).

Principles for the preparation of the half-year condensed consolidated financial statements

The accounting standards applied to prepare this Half-Year Report are consistent with those used for the Consolidated Annual Financial Statements at 31 December 2023, supplemented by the new standards as described in paragraph "New accounting standards".

These Half-Year Condensed Consolidated Financial Statements were prepared in compliance with the International Financial Reporting Standards ("IFRSs"), as issued by the International Accounting Standards Board ("IASB") and endorsed by the European Union. The designation IFRSs also includes the International Accounting Standards ("IASs") that are still in effect and all the interpretations of the International Financial Reporting Interpretations Committee ("IFRIC").

This Half-Year Report was prepared in accordance with the requirements of the relevant international accounting standard (IAS 34 - Interim Financial Reporting).

The notes provide information in summary form, in order to avoid duplicating information published previously, as required by IAS 34. Specifically, these notes discuss only those components of the income statement and balance sheet the composition or change in amount of which require comment (due to the amount involved or the type of transaction or because an unusual transaction is involved) in order to understand the Group's economic, financial and operating position.

Consequently, these Half-Year Condensed Consolidated Financial Statements do not provide all the disclosure required in the Annual Financial Statements and should be read in conjunction with the Annual Consolidated Financial Statements prepared for the year ended 31 December 2023.

When preparing the Half-Year Financial Report, management is required to develop estimates and assumptions that affect the amounts shown for revenues, expenses, assets and liabilities in the financial statements and the disclosures provided with regard to contingent assets and liabilities on the date of the interim financial statements. If such estimates and assumptions, which were based on management's best projections, should differ from actual events, they will be modified appropriately when the relevant events produce the abovementioned differences.

Moreover, certain valuation processes, particularly the more complex processes such as determining whether the value of non-current assets has been impaired, are carried out fully only in connection with the preparation of the annual financial statements, when all the necessary information is available, except when there are impairment indicators that require an immediate evaluation of any impairment losses that may have occurred.

For the purposes of preparing the Half-Year Condensed Consolidated Financial Statements the necessary valuations were carried out to determine the provisions for employees' benefits, supplementary customer indemnity and the stock option plans.

All the other items that are subject to valuation are described in the notes to the consolidated financial statements at 31 December 2023.

The income tax liability is recognized using the best estimate of the weighted average tax rate projected for the entire year referable to the companies included in the scope of consolidation.

In these Half-Year Condensed Consolidated Financial Statements, all amounts are denominated in Euros and rounded to thousands of euros, unless otherwise stated.

Financial statements presentation formats

The following provides the presentation formats and classification criteria adopted by the Group in respect of the accounting options set forth in IAS 1 - Presentation of financial statements:

- the Consolidated Statement of Financial Position has been prepared by classifying assets and liabilities according to the "current/non-current" criteria";
- the Consolidated Income Statement and the Comprehensive Consolidated Income Statement have been prepared by classifying expenses by function in addition to profit (loss) of the period, other changes in equity other than transactions carried out with Company's shareholders. This classification of the income statement, or by destination, is representative of the format used for internal reporting and management purposes and is in line with international practice in the relevant sector;
- the Consolidated Statement of Cash flows is presented by stating cash flows provided by operating activities according to the "indirect method".
- in accordance with Consob Resolution no. 15519 of 28th July 2006, within the consolidated income statement income and expenses from non-recurring transactions are identified separately; similarly, the financial statements show separately any balances related to receivable/payable positions and transactions with related parties, which are further described in Note "Transactions with related parties" to the financial statements.

The Half-Year Condensed Consolidated Financial Statements were prepared based on the conventional historical cost criterion, except for the measurement of financial assets and liabilities in those cases in which the use of the fair value criterion is mandatory.

Scope of consolidation

These Half-Year Condensed Consolidated Financial Statements include the financial statements of Diasorin S.p.A., the Group's Parent Company, and those of its subsidiaries at 30 June 2024.

Subsidiaries are companies over which Diasorin S.p.A, directly or indirectly, has the right to exercise control, as defined in IFRS 10 "Consolidated Financial Statements".

In order to assess the existence of control, the following three requirements are to be satisfied:

- power over the company;
- exposure to the risks and rights deriving from the variable returns entailed by its involvement;
- ability to affect the company so as to influence the investor's (positive or negative) results.

Subsidiaries are consolidated line by line from the date the Group obtains control until the moment when control ceases to exist.

The Group has subsidiaries neither with significant non-controlling interests nor unconsolidated structured entities and it is not subject to significant restrictions concerning interests in subsidiaries.

No changes occurred in the scope of consolidation compared to 31 December 2023.

A list of direct and indirect investments in subsidiaries at 30 June 2024 and at 31 December 2023 is provided below:

Company	Country	At 30 June 2024		At 31 December 2023	
		% held by the Group	% non-controlling interests	% held by the Group	% non-controlling interests
Direct interests					
Diasorin Italia S.p.a.	Italy	100%	-	100%	-
DiaSorin S.A/N.V.	Belgium	100%	-	100%	-
DiaSorin Ltda	Brazil	100%	-	100%	-
DiaSorin S.A.	France	100%	-	100%	-
DiaSorin Iberia S.A.	Spain	100%	-	100%	-
DiaSorin Ltd	United Kingdom	100%	-	100%	-
DiaSorin Inc.	United States	100%	-	100%	-
DiaSorin Mexico S.A de C.V.	Mexico	100%	-	100%	-
DiaSorin Deutschland GmbH	Germany	100%	-	100%	-
DiaSorin AB	Sweden	100%	-	100%	-
DiaSorin Ltd	Israel	100%	-	100%	-
DiaSorin Austria GmbH	Austria	100%	-	100%	-
DiaSorin Czech s.r.o.	Czech Republic	100%	-	100%	-
DiaSorin South Africa (PTY) Ltd	South Africa	100%	-	100%	-
DiaSorin Australia (Pty) Ltd	Australia	100%	-	100%	-
DiaSorin Ltd	China	76%	24%	76%	24%
DiaSorin Switzerland AG	Switzerland	100%	-	100%	-
DiaSorin Poland sp. z o.o.	Poland	100%	-	100%	-
DiaSorin I.N. Limited	Ireland	100%	-	100%	-
DiaSorin APAC Pte Ltd	Singapore	100%	-	100%	-
DiaSorin Middle East FZ-LLC	UAE	100%	-	100%	-
Indirect interests					
DiaSorin Canada Inc	Canada	100%	-	100%	-
DiaSorin Healthcare India Private Limited	India	100%	-	100%	-
DiaSorin Molecular LLC	United States	100%	-	100%	-
Luminex Corporation	United States	100%	-	100%	-
Nanosphere LLC	United States	100%	-	100%	-
ChandlerTec LLC	United States	100%	-	100%	-
Iris Biotech LLC	United States	100%	-	100%	-
Amins LLC	United States	100%	-	100%	-
Luminex Molecular Diagnostics Inc.	Canada	100%	-	100%	-
Luminex 2 B.V.	Netherlands	100%	-	100%	-
Luminex Japan Corp. Lts.	Japan	100%	-	100%	-
Luminex Trading (Shanghai) Co. Ltd.	China	100%	-	100%	-
Luminex Hong Kong Ltd.	Hong Kong	100%	-	100%	-

A complete list of the investee companies containing information about head office locations and the Group's ownership percentage is provided in Annex I.

New accounting standards

Below are the international accounting standards, interpretations and amendments to existing accounting standards and interpretations or specific provisions contained in the standards and interpretations approved by the IASB, which have been endorsed or have not been endorsed for adoption in Europe as of the date on which this document is approved.

New documents issued by the IASB and endorsed by the EU to be compulsorily adopted for financial statements for reporting periods beginning on 1 January 2024.

Document title	Date of issue	Effective date	Date of endorsement	EU Regulation and date of publication
Amendments to IAS 7 Statement of Cash Flows and IFRS 7 Financial Instruments: Disclosures: Supplier Finance Arrangements	25 May2023	1 January 2024	15 May 2024	16 May 2024
Amendments to IAS 1 Presentation of Financial Statements: • Classification of Liabilities as Current or Non-current; • Classification of Liabilities as Current or Non-current - Deferral of Effective Date; and • Non-current Liabilities with Covenants	23 January 2020 15 July 2020 31 October 2022	1 January 2024	19 December 2023	20 December 2023
Amendments to IFRS 16 Leases: Lease Liability in a Sale and Leaseback	22 September 2022	1 January 2024	20 November 2023	21 November 2023

IAS/IFRS and related IFRIC interpretations applicable to financial statements for reporting periods beginning after 1 January 2024 and/or documents NOT yet endorsed by the EU at 30 June 2024.

Please note that these documents shall apply only after endorsement by the EU.

Document title	Date of issue by the IASB	Effective Date of the IASB Document	Date of expected endorsement by the EU
Amendments			
Sale or contribution of assets between an investor and its associate or joint venture (Amendments to IFRS 10 and IAS 28)	September 2014	Postponed until completion of IASB project on the equity method	Endorsement suspended, pending the conclusion of IASB project on the equity method
IFRS 19 Subsidiaries without Public Accountability: Disclosures	9 May 2024	1 January 2027	TBD
IFRS 18 Presentation and Disclosure in Financial Statements	9 April 2024	1 January 2027	TBD
Amendments to IAS 21 The Effects of Changes in Foreign Exchange Rates: Lack of Exchangeability	15 August 2023	1 January 2025	TBD
Amendments to the Classification and Measurement of Financial Instruments (IFRS 9 and IFRS 7)	May 2024	1 January 2026	31 May 2024

The Group will adopt these new standards, amendments and interpretations, based on the date of application provided for and when endorsed by the European Union. The Company is currently considering the possible effects of the introduction of these amendments on the Consolidated Financial Statements.

New accounting standards endorsed and adopted by the Group

This note presents the impact of the adoption of amendments to the accounting standards, which are effective as from 1 January 2024, on the consolidated financial statements to the extent that they differ from those applied in the previous periods.

Supplier Finance Arrangements - Amendments to IAS 7 and IFRS 7

In May 2023, the IASB issued amendments to IAS 7 Statement of Cash Flows and IFRS 7 Financial instruments: Disclosures, to clarify the characteristics of reverse factoring arrangements and provide additional information on such agreements. The amendments clarify the characteristics of supplier financing arrangements and provide additional information on such arrangements. The disclosure requirements provided by the amendments aim to help users of financial statements understand the effects of supplier financing arrangements on company's liabilities, cash flows and exposure to liquidity risk. The amendments did not impact the Half-Year Consolidated Financial Statements of the Group.

Amendments to IFRS 16: Lease Liability in a Sale and Leaseback

In September 2022, the IASB issued amendments to IFRS 16 to specify the requirements that a lessee uses in measuring the lease liability arising in a sale & lease back transaction in a way that it does not recognize any amount of the gain or loss that relates to the right of use it retains. The amendments did not impact the Half-Year Consolidated Financial Statements of the Group.

Amendments to IAS 1: Classification of Liabilities as Current or Non-current

The amendments clarify how liabilities should be classified as either current or non-current, depending on the rights that exist at the end of the reporting period. The classification is not affected by company's expectations or events occurring after the reporting date. The amendments clarify what IAS 1 means when it refers to the "settlement" of a liability. Any amendments to the classification of liabilities shall be applied retrospectively, as required by IAS 8 - Accounting Policies, Changes in Accounting Estimates and Errors. The amendments did not impact the Half-Year Consolidated Financial Statements of the Group.

New accounting standards issued but not yet adopted by the Group and/or not yet endorsed

Sale or contribution of assets between an investor and its associate or joint venture (Amendments to IFRS 10)

Sale or contribution of assets between an investor and its associate or joint venture (Amendments to IFRS 10 and IAS 28). The amendments clarify the accounting treatment for sale or contribution of assets between an Investor and its Associate or Joint Venture. The accounting treatment depends on whether the non-monetary asset sold or conferred constitutes a business (as defined by IFRS 3 - Business Combinations). Where the non-monetary assets constitute a business, the investor will recognize the full gain or loss on the sale or contribution of assets. If the assets do not meet the definition of a business, the gain or loss is recognized by the investor only to the extent of the other investor´s interests in the associate or joint venture. The amendments apply prospectively. The scope of consolidation does not include associated companies and joint ventures, therefore no impacts on the Group's consolidated financial statements are expected from the application of these amendments.

IFRS 19 Subsidiaries without Public Accountability: Disclosures

IFRS 19 aims to simplify the disclosure requirements to be reported in the notes to the financial statements for a large number of companies controlled by groups that apply international accounting standards, in order to facilitate transitions to such standards for companies that apply local gaaps for the preparation of their local financial statements.

IFRS 18 Presentation and Disclosure in Financial Statements

The new IFRS accounting standard will introduce new significant requirements for presentation and disclosure in the financial statements, with a focus on the income statement, including requirements for the presentation of subtotals, aggregation and disaggregation of information, as well as disclosure of performance measures.

Amendments to IAS 21 The Effects of Changes in Foreign Exchange Rates: Lack of Exchangeability

The IASB published the document Lack of Exchangeability (Amendments to IAS 21). The amendment clarifies whether a currency is exchangeable into another currency and when it is not to determining the exchange rate to use and the disclosures to provide in the explanatory notes. The amendment shall enter into force on 1 January 2025. Earlier application is permitted.

Amendments to the Classification and Measurement of Financial Instruments (IFRS 9 and IFRS 7)

The amendments were published by the IASB in May 2024 and endorsed by the European Commission on 31 May 2024. The amendments are effective for reporting periods beginning on or after 1 January 2026.

The changes introduced relate to the following matters:

a) clarifications about the date of recognition and derecognition of some financial assets and liabilities, with a new exception for some financial liabilities settled through an electronic cash transfer system;
b) clarification and further guidance for assessing whether a financial asset meets the SPPI test;
c) addition of new disclosures for certain instruments with contractual terms that can change cash flows (such as some instruments with features linked to the achievement environment, social and governance (ESG) targets);
d) update of the disclosures for equity instruments designated at fair value through other comprehensive income (FVOCI).

ANALISYSIS OF FINANCIAL RISKS

The financial risks to which the Group is exposed include market risks and, to a lesser extent, credit risk and liquidity risk.

The table below lists material assets/liabilities by category in accordance with the requirements of IFRS 7:

		6/30/2024				12/31/2023			
(in thousands of Euros)	**Notes**	**Carrying Value**	**Assets at amortized cost**	**Assets at fair value**	**Assets at fair value with changes in the Comprehensive Income Statement**	**Carrying Value**	**Assets at amortized cost**	**Assets at fair value**	**Assets at fair value with changes in the Comprehensive Income Statement**
Trade receivables	(17)	195,396	188,853	6,543	-	198,560	198,560	-	-
Financial derivatives	(21)	21,706	-	-	21,706	24,639	-	64	24,575
Cash and cash equivalents	(19)	169,570	169,570	-	-	280,314	280,314	-	-
Current financial assets	(21)	47,297	47,297	-	-	98,437	98,437	-	-
Total current financial assets		***433,969***	***405,720***	-	***21,706***	***601,950***	***577,311***	***64***	***24,575***
Financial derivatives	(21)	9,381	-	-	9,381	12,891	-	-	12,891
Total non-current financial assets		***9,381***	***-***	-	***9,381***	***12,891***	***-***	***-***	***12,891***
Total financial assets		**443,350**	**405,720**	**6,543**	**31,087**	**614,841**	**577,311**	**64**	**37,466**

		6/30/2024			12/31/2023		
(in thousands of Euros)	**Notes**	**Carrying Value**	**Liabilities at amortized cost**	**Liabilities at fair value**	**Carrying Value**	**Liabilities at amortized cost**	**Liabilities at fair value**
Liabilities for Put/Call option rights classified in other non-current liabilities	(24)	5,011	-	5,011	5,011	-	5,011
Financial lease liabilities (IFRS 16) classified in other non-current liabilities	(21)	66,129	66,129	-	62,090	62,090	-
Non-current financial liabilities	(21)	903,380	903,380	-	1,020,915	1,020,915	-
Total non-current financial liabilities		***974,520***	***969,509***	***5,011***	***1,088,017***	***1,083,006***	***5,011***
Trade payables	(25)	98,667	98,667	-	100,706	100,706	-
Financial lease liabilities (IFRS 16) classified in current financial liabilities	(21)	8,095	8,095	-	8,910	8,910	-
Current financial liabilities	(21)	51,514	51,514	-	100,738	100,738	-
Total current financial liabilities		***158,276***	***158,276***	***-***	***210,355***	***210,355***	***-***
Total financial liabilities		**1,132,796**	**1,127,785**	**5,011**	**1,298,371**	**1,293,360**	**5,011**

With regard to the above, classification of financial assets and liabilities measured at fair value in the statement of financial position, according to the fair value hierarchy, concerned derivative financial instruments at 30 June 2024. These instruments are classified at level 2 and entered into other current financial assets amounting to € 31,087 relating to IRS contracts.

As to current financial assets, the Group used part of its liquidity denominated in U.S. dollars in short-term liquidity management tools (time deposits).

With regard to liabilities for put/call options, the amount refers to the rights envisaged by the Joint Venture contract in China that have been entered according to IAS 32 and IFRS 9 accounting standards. Specifically, the JV contract, which contains an obligation for the Group to purchase its own equity instruments for cash or other financial assets, gives rise to a financial liability for the present value of the redemption amount. Such amount is not included in the net financial debt.

Non-current financial liabilities and assets are settled or valued at market rates, so their fair value is substantially in line with the current book value.

Length of financial liabilities is provided in Note 21.

Risks related to fluctuations in foreign exchange and interest rates

The Group is exposed to market risk deriving from currency and interest rate fluctuations as it operates in an international framework in which transactions are made in different currencies and interest rates.

As to interest rates, the Group used Interest Rate Swaps as hedges against the debt in U.S. dollars (on which interest accrues at a floating rate) of the subsidiary DiaSorin Inc., with the recognition of a net positive fair value of € 31,087 thousand at 30 June 2024.

Interests do not accrue on the convertible bond issued in Euros by the Group's Parent Company, therefore there are no risks deriving from an interest rate increase.

Some Group subsidiaries are located in countries that are not members of the European Monetary Union. Since the Group's reporting currency is the euro, the income statements of these companies are translated into euros at the average exchange rate for the year. Consequently, even if revenues and margins were to remain equal when stated in the local currency, fluctuations in exchange rates could have an impact on the euro amount of revenues, expenses and operating results due to the translation into the consolidation currency. Assuming a 5% change in the exchange rates of all the currencies used by the Group, the impact on the operating result would be of about € 4 million.

The euro amount attributed to assets and liabilities of consolidated companies that use reporting currencies different from the euro could vary as a result of changes in exchange rates. As required by the accounting standards adopted by the company, these changes are recognized directly in equity by posting them to the "currency translation reserve". A 5% change in all foreign exchange rates would have an impact of about € 83 million.

Credit risk

The Group's receivables present a low level of risk both due to the sector in which Diasorin operates where end customers are, to a large extent, public institutions and due to the high financial soundness of its main private customers. Considering the Group's economic and financial performance, the economic scenario caused by the COVID-19 pandemic had no material impact on the Group's trade receivables and, therefore, it was not necessary to adjust the determination of the recoverability of receivables recognized in the balance sheet and expected credit losses, according to the model defined by the IFRS 9 standard.

At 30 June 2024 past-due trade receivables were equal to about 8% of revenues and refer to the Italian and U.S. subsidiaries. These past-due receivables were covered by an allowance for doubtful accounts amounting to € 11,277 thousand. In addition, in order to bridge the gap between contractual payment terms and actual collection times, the Group resorts to factoring receivables without recourse.

A breakdown of trade receivables and provision for doubtful accounts is as follows:

Type	**Expiring**	**0 - 90**	**91 - 180**	**181 - 360**	**Pat due for over 360**	**Total due**	**Total receivables**
Trade receivables	155,757	32,789	3,895	4,833	9,399	50,917	206,674
Expected loss rate	***0%***	***2%***	***17%***	***40%***	***87%***	***22%***	***n.a***
Provision for doubtful account	-	(518)	(670)	(1,932)	(8,157)	(11,277)	(11,277)
Net value	**155,757**	**32,271**	**3,225**	**2,902**	**1,242**	**39,639**	**195,396**

Liquidity risk

A prudent cash management strategy includes maintaining sufficient cash or readily available assets and credit lines to meet immediate liquidity needs. Cash flows, the need for financing and liquidity are monitored and managed centrally, in order to promptly guarantee an effective raising of the financial resources or an adequate employment of the liquidity available.

In order to meet any financial needs and a credit market characterized by low liquidity, the Parent Company has deemed it necessary, in 2022, to adopt a EUR 150 million 3 year committed revolving credit facility, made available by a pool of banks and to be used upon set conditions. At 30 June 2024, the Group used about € 51,514 thousand of this credit facility.

Management believes that the funds and credit facilities currently available, when combined with the resources generated by operating and financing activities, will enable the Group to meet the obligations resulting from its capital investment programs, working capital requirements and the need to repay its indebtedness upon maturity.

At 30 June 2024, cash and cash equivalent were € 169,570 thousand and investments in money market instruments with maturity within 12 months were € 47,298 thousand.

As regards the net financial debt, the following should be noted:

- the repayment, in January, of a principal of USD 50,000,000 and, in April, of a principal of USD 150,000,000 relating to the “Term Loan”, plus € 5,682 thousand in interest payment;
- Convertible bond amounting to € 462,471 thousand;
- Use of a revolving credit facility for € 39,867 thousand for dividend payment to shareholders;
- Opening and use of a credit line granted to the Chinese subsidiary for an amount equal to € 11,647 thousand;
- Use of the liquidity held by Diasorin Inc. in Time Deposits for € 47,298 thousand, down from € 50,855 thousand at 31 December 2023.

A breakdown of the net consolidated financial debt is as follows:

	(in thousands of Euros)	**6/30/2024**	**12/31/2023**	**Change**
A	Cash on hand	169,570	280,314	(110,744)
B	Cash equivalent	-	-	-
C	Other current financial assets	47,298	98,437	(51,139)
D	**Liquidity (A+B+C)**	**216,868**	**378,751**	**(161,883)**
E	Current financial debt (including debt instruments, but excluding the current portion of non-current financial debt)	59,609	63,346	(3,737)
F	Current portion of non-current financial debt	-	21,728	(21,728)
G	**Current financial debt (E+F)**	**59,609**	**85,074**	**(25,465)**
H	**Net current financial debt (G-D)**	**(157,259)**	**(293,677)**	**136,418**
I	Non-current financial debt (excluding the current portion and debt instruments)	475,952	612,254	(136,301)
J	Debt instruments	462,471	457,797	4,674
K	Trade payables and other non-current debts	-	-	-
L	**Non-current financial debt (I+J+K)**	**938,423**	**1,070,050**	**(131,626)**
M	**Total financial debt (H+L)**	**781,163**	**776,373**	**4,790**

Risk related to the geopolitical and macroeconomic context

The Russian-Ukrainian and Israeli-Palestinian geopolitical conflicts have continued to bring about significant changes in the global scenario and are having a widespread economic impact. It should be noted, however, that the Group's exposure to these markets is not particularly significant and therefore the Group does not foresee material negative impacts deriving from these conflicts.

Risk related to the climatic and environmental context

The Group is not exposed to particular risks related to the climatic and environmental context, considering the sector and industry in which it operates.

SEGMENT INFORMATION

In accordance with IFRS 8, the Company designated the geographic regions where it operates as its operating segments.

The Group's organization and internal management structure, and its performance analysis and reporting system are segmented as follows: Italy and U.K. Branch, Europe (Germany, France, Belgium and the Netherlands, Spain and Portugal, Ireland, Austria, Great Britain, Scandinavia, Czech Republic, Slovakia, Switzerland and Poland), North America (United States and Canada) and Rest of the World (Brazil, Mexico, Israel, China, Australia, India, and South Africa).

The Group is characterized by an organization of its commercial structure by geographic regions, which was adopted to accommodate the Group's geographic expansion and strategic initiatives. The structure of this organization reflects the destination of the Group's sales, dividing the sales areas into four regions: Europe and Africa, North America, Latin America, Asia Pacific and China.

As a result of the above, the communication of the financial data of the DiaSorin Group to the financial markets and the investing public is being changed to show revenue data aligned with its organization by regions.

The schedules that follow show the Group's operating and financial data broken down by geographic region identifying, as required by IFRS, 8 paragraph 5:

- Activities generating revenues and expenses (including revenues and expenses relating to transactions with other components of the same entity);
- Operating results that are regularly reviewed by the entity's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance; and
- Discrete financial information about assets, liabilities, revenues and expenses.

No unallocated common costs are shown in the abovementioned schedules as each Country and hence each segment is equipped with comprehensive independent organizations (sales, technical support and accounting) fully capable of exercising its functions. Moreover, Italy segment invoices each quarter to the other segments the activities costs that are incurred centrally by the corporate structure to support Group's companies.

Eliminations refer primarily to inter-segment margins that are eliminated at consolidation. Specifically, the elimination of the margin earned by Italy segment through the sale of equipment to other segments is carried out both at the result and investment levels. The margin generated by products sold by the manufacturing locations to the commercial branches but not yet sold to outsiders is eliminated only at the result level.

Segment assets include all operating items (non-current assets, receivables and inventory) but not tax-related items (deferred-tax assets) and financial assets, which are shown at Group level

The same approach was used for segment liabilities, which include operating items (mainly trade payables and amounts owed to employees) but do not include financial and tax liabilities or shareholders' equity, which are shown at Group level.

	ITALY		EUROPE		NORTH AMERICA		REST OF THE WORLD		ELIMINATIONS		CONSOLIDATED	
(in thousands of Euros)	**2024**	**2023**	**2024**	**2023**	**2024**	**2023**	**2024**	**2023**	**2024**	**2023**	**2024**	**2023**
INCOME STATEMENT												
Revenues from customers	87,671	89,101	145,468	132,572	304,507	304,580	51,560	50,137	-	-	589,206	576,390
Inter-segment revenues	152,232	139,008	10,600	9,422	67,105	61,507	-	0	(229,937)	(209,937)	-	-
Total revenues	**239,903**	**228,109**	**156,068**	**141,994**	**371,612**	**366,087**	**51,560**	**50,137**	**(229,937)**	**(209,937)**	**589,206**	**576,390**
Segment revenues	**42,137**	**32,436**	**20,532**	**18,167**	**80,850**	**61,070**	**625**	**(2,516)**	**(12,426)**	**8,237**	**131,718**	**117,396**
Unallocated common costs											-	-
Operating margin											**131,718**	**117,396**
Other net income (expense)											-	-
Financial income (expense)											(7,686)	(4,592)
Result before taxes											**124,033**	**112,804**
Income taxes											(28,528)	(25,945)
Net result											**95,504**	**86,859**
OTHER INFORMATION												
Investments in intangibles	8,625	4,337	41	4	29,095	24,003	2,453	677	-	-	40,214	29,021
Investments in prop. plant and equip.	9,884	14,479	4,697	4,497	17,419	8,979	1,562	2,304	(852)	(741)	32,710	29,518
Total investments	**18,509**	**18,816**	**4,738**	**4,501**	**46,514**	**32,982**	**4,015**	**2,981**	**(852)**	**(741)**	**72,924**	**58,539**
Amortization in intangibles	(5,475)	(5,499)	(3,495)	(3,482)	(30,153)	(29,626)	(526)	(473)	2,448	2,328	(37,201)	(36,752)
Depreciation of prop. plant and equip.	(8,116)	(7,921)	(5,261)	(5,559)	(12,544)	(13,523)	(2,648)	(2,409)	1,119	1,172	(27,450)	(28,240)
Total amortization and depreciation	**(13,591)**	**(13,420)**	**(8,756)**	**(9,041)**	**(42,697)**	**(43,149)**	**(3,174)**	**(2,882)**	**3,567**	**3,500**	**(64,651)**	**(64,992)**

	ITALY		EUROPE		NORTH AMERICA		REST OF THE WORLD		ELIMINATIONS		CONSOLIDATED	
	6/30/2024	12/31/2023	6/30/2024	12/31/2023	6/30/2024	12/31/2023	6/30/2024	12/31/2023	6/30/2024	12/31/2023	6/30/2024	12/31/2023
STATEMENT OF FINANCIAL POSITION												
Segment assets	548,121	535,881	176,185	182,166	2,365,501	2,269,622	80,237	80,349	(323,809)	(304,698)	2,846,223	2,763,319
Assets held for sale											-	-
Unallocated assets											279,290	448,120
Total assets	**548,121**	**535,881**	**176,185**	**182,166**	**2,365,501**	**2,269,622**	**80,237**	**80,349**	**(323,809)**	**(304,698)**	**3,125,513**	**3,211,439**
Segment liabilities	170,564	166,413	92,181	102,126	219,453	217,774	29,911	31,926	(255,838)	(246,415)	256,271	271,823
Liabilities connected to assets held for sale											-	-
Unallocated liabilities											1,254,430	1,401,648
Shareholders' equity											1,614,813	1,537,968
Total liabilities	**170,564**	**166,413**	**92,181**	**102,126**	**219,453**	**217,774**	**29,911**	**31,926**	**(255,838)**	**(246,415)**	**3,125,513**	**3,211,439**

Description and main changes

Consolidated income statement

1. Revenues

In the first half of 2024, revenues were € 589,206 thousand (€ 576,390 thousand in the first half of 2023), up 2.2% compared to the first half of 2023 and refer mainly to the sale of diagnostic kits.

A breakdown of revenues by customer location in outlet markets is provided below:

(in thousands of Euros)	**1st half 2024**	**1st half 2023**	**% Change**
Europe direct	206,976	191,928	7.8%
North America direct	279,084	255,044	9.4%
Rest of the World	89,045	94,761	-6.0%
COVID	14,101	34,658	-59.3%
Total Revenues	**589,206**	**576,390**	**2.2%**

2. Cost of sale

In the first half of 2024, the cost of sales was € 199,273 thousand, as against € 197,705 thousand in the first half of 2023. The item includes, in addition to costs for diagnostic kits production, royalties expense amounting to € 23,308 thousand (€ 19,680 thousand in the first half of 2023), costs incurred to distribute products to end customers totaling € 7,663 thousand (€ 8,608 thousand in the first half of 2023) and depreciation of Group's equipment held by customers equal to € 9,927 thousand (€ 10,829 thousand in the first half of 2023).

3. Sales and marketing expenses

In the first half of 2024, sales and marketing expenses amounted to € 141,224 thousand, as against € 141,934 thousand in the same period of 2023. in the previous year. This item consists mainly of marketing costs incurred to promote and distribute Diasorin products, costs attributable to the direct and indirect sales force and the cost of the technical support offered together with the Group-owned equipment provided to customers.

Amortizations of intangibles deriving from the Luminex acquisition were € 19,401 thousand, mainly attributable to sales and marketing expenses, as against € 19,118 thousand in the first half of 2023.

4. Research and development costs

In the first half of 2024, research and development costs, which totaled € 43,233 thousand (€ 46,355 thousand in the first half of2023), include the research and development outlays that were not capitalized, equal to € 17,953 thousand (€ 18,569 thousand in the first half of 2023), costs incurred to register the products offered for sale and meet quality requirements totaling € 16,092 thousand (€ 17,043 thousand in the first half of 2023) and the amortization of capitalized development costs equal to € 9,188 thousand (€ 10,743 thousand in the first half of 2023). In the first half of 2024, the Group capitalized development costs amounting to € 38,312 thousand, as against € 27,804 thousand in the first half of 2023.

5. General and administrative expenses

General and administrative expenses, which include expenses incurred for corporate management activities, Group administration, finance and control, information technology, corporate organization and insurance, were € 64,141 thousand in the first half of 2024 (€ 61,400 thousand in the first half of 2023).

6. Other operating income (expense)

A breakdown of other operating income and expense in the first half of 2024 is as follows:

(in thousands of Euros)	**2024**	**2023**
Tax charges	(1,078)	(858)
Accruals and release of provisions	(1,024)	2,075
Other operating (expense) and income	(5,334)	(4,429)
Non-recurring charges- other	(2,181)	(8,388)
Other operating (expense) and income	**(9,617)**	**(11,602)**

The item Other operating (expense) and income include income and expense from ordinary operations that cannot be allocated to specific functional areas (such as gains and losses on asset sales, government grants, insurance settlements, reversals of excess provisions and incidental taxes and fees).

7. Financial income

In the first half of 2024, the Group's financial income amounted to € 6,462 thousand (€ 10,680 thousand in the first half of 2023), mainly resulting from interest income accrued on time deposits to manage the company's liquidity denominated in U.S. dollars (€ 3,515 thousand).

8. Financial expenses

Financial expenses are detailed in the table below:

(in thousands of Euros)	**2024**	**2023**	**Change**
Factoring transactions fees	(625)	(327)	(298)
Interest expenses and other financial expenses	(12,931)	(14,392)	1,461
Including: interest expense on leases	(1,709)	*(1,459)*	*(250)*
Interest on pension funds	(592)	(554)	(38)
Total financial expenses	**(14,148)**	**(15,272)**	**1,124**

In the first half of 2024, financial expenses amounted to € 14,148 thousand, as against € 15,272 thousand in the first half of 2023.

Interest expenses and other financial expenses include:

- € 4,674 thousand in financial expenses at amortized cost relating to the convertible bond issued by the Group's Parent Company (€ 5,209 thousand in 2023);
- € 4,371 thousand relating to the bank loan to finance the acquisition of the Luminex Group (€ 5,771 thousand in 2023);
- € 1,709 thousand in interest expenses on leases recognized under the IFRS16 accounting standard (€ 1,459 thousand in 2023).

- € 963 thousand for the negative change of the ineffective Mark-to-Market component of the IRS derivative to hedge the Term Loan taken out for financing the Luminex acquisition.

9. Income taxes

Income taxes recognized in the income statement amounted to € 28,528 thousand in the first half of 2024 (€ 25,945 thousand in the first half of 2023). The tax rate was 23%, broadly in line with the first half of 2023.

Amendments to IAS 12 have been introduced in response to BEPS Pillar Two rules of the OECD and include:

- A mandatory temporary exception to the accounting for and disclosure of deferred taxes arising from the jurisdictional implementation of the Pillar Two model rules;
- Disclosure requirements for affected entities to help users of the financial statements better understand an entity's exposure to income taxes arising from that legislation, particularly before its effective date.

The mandatory temporary exception applies immediately. The Diasorin Group is subject to the application of the OECD Pillar Two rules and makes use of exception to the accounting for and disclosure of information on deferred taxes arising from the application of that legislation, as provided for by amendment to IAS 12.

The Pillar Two rules provide that the Group pays a top-up tax equal to the difference between the effective tax rate in the jurisdictions in which the Group operates and the minimum tax rate of 15%; given the jurisdictions in which the Group's companies operate, the company does not expect any significant impacts deriving from the application of such rules.

10. Earnings per share

Basic earnings per share amounted to € 1.71 in the first half of 2024 (€ 1.55 in the first half of 2023) and diluted earnings per share amounted to € 1.71 (€ 1.55 in the first half of 2023). Basic earnings per shares were computed by dividing the net profit attributable to the shareholders by the weighted average number of shares outstanding during the year, equal to 55,718,785 at 30 June 2024 and 55,880,176 in the first half of 2023.

The dilutive effect of stock option plans granted by Diasorin S.p.A. is determined by excluding tranches assigned to a higher price than the average price of Diasorin ordinary shares in the first half of 2024.

Consolidated statement of financial position

11. Property, plant and equipment

In the first half of 2024, changes that occurred in the original cost of property, plant and equipment were as follows:

(in thousands of Euros)	At 31 December 2023	Additions	Depreciations	Translation differences	Disposals	Reclassifications and other changes	At 30 June 2024
Land	5,053	-	-	96	-	-	5,149
Buildings	25,588	271	(1,009)	379	-	5,665	30,894
Plant and machinery	23,156	1,155	(1,968)	284	-	(34)	22,593
Manufacturing and distribution equipment	62,331	11,618	(14,763)	837	(1,545)	907	59,385
Other assets	42,976	4,778	(3,838)	1,101	(10)	(2,325)	42,682
Advances and tangible in progress	30,165	7,153	-	785	(12)	(2,372)	35,719
IFRS 16 rights of use	67,017	7,735	(5,872)	1,298	(913)	10	69,275
Total property, plant and equipment	**256,286**	**32,710**	**(27,450)**	**4,780**	**(2,480)**	**1,851**	**265,697**

Additions to manufacturing and distribution equipment include equipment provided to customers, equal to € 9,935 thousand in the first half of 2024 (€ 5,493 thousand in the first half of 2023). Depreciation for the period were € 9,927 thousand (€ 10,829 thousand in the first half of 2023).

Advances and tangibles in progress were € 35,719 thousand at 30 June 2024 (€ 30,165 thousand in 2023) and include advances on plant and machinery, equipment and leasehold improvements.

Tangible assets include *"Right-of-use Assets"* for a total amount of € 69,275 thousand at 30 June 2024 (€ 67,017 thousand at 31 December 2023). The item includes right-of-use assets relating to rented property and industrial buildings, amounting to € 61,595 thousand (€ 59,436 thousand at 31 December 2023), as well as right-of-use assets relating to company vehicles rentals amounting to € 7,680 thousand at 30 June 2024 (€ 7,580 thousand at 31 December 2023).

12. Goodwill and other intangible assets

Goodwill totaled € 823,412 thousand at 30 June 2024 (€ 799,365 thousand at 31 December 2023), with an increase of € 24,047 thousand due to exchange rate changes.

The table below provides a breakdown of changes in the net carrying amount of goodwill and other intangible assets in the first half of 2024:

(in thousands of Euros)	At 31 December 2023	Additions	Amortization	Translation differences	Divestments and other changes	At 30 June 2024
Goodwill	799,365	-	-	24,047	-	823,412
Development costs	338,699	38,312	(9,188)	9,558	2,700	380,081
Concessions, licenses and trademarks	111,571	663	(2,571)	(3,866)	12,961	118,759
Customer relationship	*647,798*	-	*(25,106)*	*26,488*	-	*649,179*
Industrial patents and intellectual property rights	2,527	48	(259)	(18)	-	2,298
Advances and other intangibles	25,011	1,191	(77)	308	(14,926)	11,507
Total intangible assets	**1,924,971**	**40,214**	**(37,201)**	**56,517**	**735**	**1,985,236**

Goodwill is allocated to the following CGUs:

- € 767,311 thousand to Diasorin North America CGU;
- € 46,432 thousand to CGU Diasorin Italy CGU;
- € 6,840 thousand to Diasorin Germany CGU;
- € 2,064 thousand to Diasorin Brazil CGU;
- € 765 thousand to Diasorin Benelux CGU.

In the first half of 2024, capitalized development costs were € 38,312 thousand and related to the development of the LIAISON PLEX and LIAISON NES projects.

The company Management has not identified any impairment indicators and therefore no impairment test has been carried out for intangible assets with an indefinite useful life.

The company Management will update its assessments through an impairment test that will be fully developed during the preparation of the annual financial statements at 31 December 2024.

13. Equity investments

Non-consolidated equity investments totaled € 26 thousand at 30 June 2024 and refer to shares in non-controlled companies. No changes occurred compared to the previous year.

14. Deferred-tax assets and deferred-tax liabilities

Deferred-tax assets amounted to € 31,310 thousand at 30 June 2024 (€ 31,813 thousand at 31 December 2023). They relate to consolidated companies that have deferred-tax assets in excess of deferred-tax liabilities and to consolidation adjustments.

Deferred-tax liabilities, which totaled € 204,789 thousand at 30 June 2024 (€ 199,596 thousand at 31 December 2023) are included within liabilities in the balance sheet and relate to consolidated companies that have deferred-tax liabilities in excess of deferred-tax assets.

The balance reflects the net deferred-tax assets computed from the elimination of unrealized gains on intra-Group transactions and on temporary differences between the assets and liabilities amounts used to prepare the consolidated financial statements and the corresponding amounts used by the consolidated companies for tax purposes.

Deferred-tax assets were recognized in the financial statements when their future use was deemed to be probable and their recoverability through future taxable income computed on the basis of long-term plans prepared by the Group's Management. The same approach was used to recognize the benefit provided by the use of tax loss carryforwards, most of which, under current laws, can be brought forward indefinitely.

Based on the long-term projections prepared by the Group's Management, the Group is expected to generate sufficient taxable income in future years to allow for the full recovery of the abovementioned amounts.

An analysis of deferred-tax assets, net of offsetable deferred-tax liabilities, is provided below:

(in thousands of Euros)	**6/30/2024**	**12/31/2023**
Deferred-tax assets	31,310	31,813
Deferred-tax liabilities	(204,789)	(199,596)
Total net deferred-tax assets (liabilities)	**(173,480)**	**(167,783)**

In accordance with IAS 12, the Group recognized deferred tax assets amounting to € 10,414 thousand and relating to lease liabilities (IFRS 16), and deferred tax liabilities amounting to € 9,082 and relating to rights of use.

15. Other non-current assets

Other non-current assets amounted to € 2,993 thousand at 30 June 2024 (€ 2,760 thousand at 31 December 2023). They consist mainly of receivables from the Parent Company and the Italian, Belgian, Brazilian, Chinese and U.S. subsidiaries due beyond 12 months.

16. Inventories

A breakdown of inventories, which totaled € 327,714 thousand, is provided below:

(in thousands of Euros)	6/30/2024			12/31/2023		
	Gross amount	**Write-down allowances**	**Net amount**	**Gross amount**	**Write-down allowances**	**Net amount**
Raw materials and supplies	179,398	(20,684)	158,714	154,040	(18,123)	135,917
Work in progress	90,421	(5,178)	85,243	82,217	(5,823)	76,394
Finished goods	92,234	(8,477)	83,757	110,457	(7,267)	103,190
Total	**362,053**	**(34,339)**	**327,714**	**346,714**	**(31,214)**	**315,500**

The increase of € 12,214 thousand compared to 31 December 2023 is mainly due to materials for manufacturing Luminex instruments and immunodiagnostic reagents.

The table below shows the changes that occurred in the allowance for inventory write-downs:

(in thousands of Euros)	**6/30/2024**	**12/31/2023**
Opening balance	**31,214**	**35,525**
Additions for the period	2,624	13,875
Utilizations/Reversals for the period	(268)	(16,931)
Translation differences and other changes	769	(1,256)
Closing balance	**34,339**	**31,214**

17. Trade receivables

Trade receivables were € 195,396 thousand at 30 June 2024 (€ 198,560 thousand at 31 December 2023).

The allowance for doubtful accounts amounted to € 11,277 thousand. The table that follows shows the changes compared to 31 December 2023:

(in thousands of Euros)	**6/30/2024**	**12/31/2023**
Opening balance	**11,247**	**13,504**
Additions for the period	1,043	154
Utilizations/Reversals for the period	(150)	(234)
Translation differences and other changes	(863)	(2,177)
Closing balance	**11,277**	**11,247**

In order to bridge the gap between contractual payment terms and actual collection terms, the Group uses factoring transactions to assign its receivables without recourse. In the first half of 2024, the receivables liquidated by the Italian subsidiary amounted to € 21,879 thousand (€ 42,821 thousand at 31 December 2023).

18. Other current assets

Other current assets amounted to € 69,187 thousand at 30 June 2024 (€ 65,243 thousand at 31 December 2023) and include tax credit, among which € 33,300 thousand for IRES and IRAP tax receivables held by the Group's Parent company and its Italian subsidiary.

19. Cash and cash equivalent

Cash and cash equivalents amounted to € 169,570 thousand at 30 June 2024 (€ 280,314 thousand at 31 December 2023). They consist of ordinary bank accounts and similar money market instruments. More detailed information is provided in the Statement of Cash Flows.

20. Shareholders' equity

Share capital

At 30 June 2024, the fully paid-in share capital consisted of 55,948,257 common shares, par value of € 1 each. No changes occurred compared with 31 December 2023.

Treasury shares

At 30 June 2024, the amount of treasury shares was 2,632,381, equal to 4.71% of the share capital, totaling € 301,338 thousand (€ 296,797 thousand at 31 December 2023).

The increase of € 4,541 thousand compared to 31 December 2023, reflects the net effect deriving from the purchase of treasury shares (equal to € 8,135 thousand), and from the exercise of 9,699 total options relating to the 2016 Stock Option Plan (4,699 options) and to the 2017 Stock Option Plan (5,000 options), for a total value of € 806 thousand and from the assignment of the second tranche of shares in relation to the 2022 equity plan and the first tranche of shares in relation to the 2023 equity plan for an amount equal to € 2,999 thousand.

Additional paid-in capital

This reserve amounted to € 18,155 thousand at 30 June 2024 and no changes occurred compared with 31 December 2023.

Statutory reserve

This reserve amounted to € 11,190 thousand and no changes occurred compared with 31 December 2023.

Other reserve and retained earnings

The item is broken down as follows:

(in thousands of Euros)	**6/30/2024**	**12/31/2023**	**Change**
Currency translation reserve	117,258	67,509	49,749
Reserve for treasury shares	301,338	296,797	4,541
Stock option reserve	36,891	32,240	4,651
Gains/(losses) on remeasurement of defined benefit plans	(6,117)	(6,139)	21
Retained earnings	1,388,671	1,290,099	98,572
IFRS transition reserve	(2,973)	(2,973)	-
Other reserves	(99,040)	(87,331)	(11,708)
Total Other reserves and retained earnings	**1,736,029**	**1,590,203**	**145,825**

Currency translation reserve

The currency translation reserve was positive by € 117,258 thousand (€ 67,509 thousand at 31 December 2023) and reflects the foreign exchange differences resulting from the translation at year-end exchange rates of the shareholders' equities of consolidated companies with financial statements denominated in foreign currencies. The positive change of € 49,749 thousand was due to the fluctuation of the exchange rate of the US dollar vis-à-vis the Euro.

Reserve for treasury shares

At 30 June 2024, the reserve for treasury shares amounted to € 301,338 thousand (€ 296,797 thousand at 31 December 2023). This reserve was established pursuant to law (Article 2357 *ter* of the Italian Civil Code). In the first half of 2024 the change in the reserve was due to the purchase of treasury shares for € 8,135 thousand, net of the exercise of 9,699 total options relating to the 2016 Stock Option Plan (4,699 options) and to the 2017 Stock Option Plan (5,000 options), for a total amount of € 806 thousand.

Stock option reserve

The balance in the stock option reserve, which amounted to € 36,891 thousand at 30 June 2024 (€ 32,240 thousand at 31 December 2023) refers to the stock option plans in effect at 30 June 2024.

On 29 April 2022, the ordinary Shareholders' Meeting approved an incentive and loyalty plan called "Equity Awards Plan" for managers and key employees of DiaSorin S.p.A. and its subsidiary. The plan will be implemented through the assignment – without consideration – of rights which, if accrued upon the fulfilment of the conditions, grant the right to receive without consideration ordinary treasury shares in the Company's portfolio, at a ratio of 1 share for every right accrued. In May 2024, the list of beneficiaries of the third assignment cycle was approved and 80,790 rights were assigned to receive shares

On 28 April 2023, the ordinary Shareholders' Meeting approved the Stock Option Plan aimed at top executives and key employees of Diasorin S.p.A., authorizing the Board of Directors to dispose of the Company's treasury shares reserving them, in the necessary or appropriate amount and under the terms established by the Plan, to serve the Plan itself.

The increase (€ 4,651 thousand) in the reserve was due to the recognition of the overall cost of the period recognized in general and administrative expenses under employee costs, whilst the decrease was attributable to the exercises of stock options and the assignments related to the second tranche of the 2022 Equity Plan and to the first tranche of the 2023 Equity Plan.

Gains/(losses) on remeasurement of defined benefit plans

The balance of the reserve was negative by € 6,117 thousand at 30 June 2024 (negative by 6,139 thousand at 31 December 2023) and the change was due to the recognition of net profits determined in the actuarial valuation of the Group's defined-benefit plans for € 21 thousand.

Retained earnings

Retained earnings amounted to € 1,388,671 thousand at 30 June 2024 (€ 1,290,099 thousand at 31 December 2023). The change of € 98,572 thousand compared to December 31, 2023, is the net result of:

- appropriation of the consolidated net profit earned by the Group in 2023 for € 159,849 thousand;
- distribution of ordinary dividends equal to € 61,277 thousand as approved on 24 April 2024 by the Ordinary Shareholders' Meeting (equal to € 1.15 per share).

IFRS transition reserve

The IFRS transition reserve was established on January 1, 2005, upon first-time adoption of the IFRSs as an offset to the adjustments recognized to make the financial statements prepared in accordance with Italian accounting standards consistent with IFRS requirements, net of the applicable tax effect (as required by and in accordance with IFRS 1). This reserve has not changed since its establishment.

Other reserves

The item, negative by € 99,040 thousand, posted a negative change of € 11,708 thousand compared to 31 December 2023, mainly as a result of the purchase of treasury shares, net of the stock options' exercise, for an amount equal to € 6,683 thousand, and of the equity component relating to the cash flow hedge reserve, equal to € 5,025 thousand.

21. Financial assets and liabilities

Payables for financial liabilities amounted to € 1,029,117 thousand at 30 June 2024 (as against financial assets amounting to € 78,384 thousand) as detailed below (amounts in thousands):

Type of financial liability	Current portion	Non-current portion	Total
Term Loan granted to Diasorin Inc.	-	440,909	440,909
Convertible Bonds issued by Diasorin S.p.A.	-	462,471	462,471
IFRS 16 lease payables	8,095	66,129	74,224
Revolving Credit Facility granted to DiaSorin S.p.A. and Diasorin China Ltd	51,514	-	51,514
Total financial liabilities	**59,609**	**969,509**	**1,029,117**
Hedging derivatives	21,706	9,381	31,086
Diasorin Inc,'s cash investments	47,298	-	47,298
Other financial derivatives	(0)		(0)
Total financial assets	**69,003**	**9,381**	**78,384**
Total net financial assets/(liabilities)	**(9,394)**	**960,128**	**950,734**

The table below lists the changes that occurred in financial assets and liabilities outstanding at 30 June 2024 (amounts in thousands of euros) compared to 31 December 2023:

Type of financial liabilities	At 31 December 2023	Additions	Repayments	Interests accrued and amortized cost	Translation differences and other changes	At 30 June 2024
Term Loan granted to DiaSorin Inc.	609,421	-	(190,645)	4,371	17,761	440,909
Convertible Bond issued by DiaSorin S.p.A.	457,797	-	-	4,674	-	462,471
Lease payables (IFRS 16)	71,001	5,818	(4,053)	-	1,458	74,224
Revolving Credit Facility granted to DiaSorin S.p.A. and to DiaSorin China Ltd	54,435	-	(3,022)	-	101	51,514
Total financial liabilities	**1,192,654**	**5,818**	**(197,720)**	**9,045**	**19,320**	**1,029,117**
Hedging derivatives	37,466	-	(7,512)	-	1,133	31,086
DiaSorin Inc.'s cash investments	98,437	-	(53,768)	-	2,629	47,298
Other current financial assets	64	-	(64)	-	-	(0)
Total financial assets	**135,966**	**-**	**(61,344)**	**-**	**3,762**	**78,384**
Total net financial liabilities	**1,056,688**	**5,818**	**(136,375)**	**9,045**	**15,558**	**950,734**

Compared to the balance at 31 December 2023, financial liabilities include the repayment of a principal of USD 200,000,000 regarding the "Term Loan":

- USD 50,000,000 in January 2024;
- USD 150,000,000 in April 2024

This line includes the payment of € 5,682 thousand in interest expense.

Interest accrues on the amount financed at an annual rate equal to SOFR plus a spread which is variable according to the value of the ratio between consolidated net financial indebtedness and consolidated EBITDA, as contractually defined. The Financing Agreement contains commitments that are customary for agreements of a similar type and size, such a guarantee and disclosure obligations, negative pledge and events of default clauses, and compliance with certain financial ratio that at 30 June 2024 complied with the requirements set. This liability is measured at amortized cost and, at 30 June 2024, amounted to € 440,909 thousand.

At 30 June 2024, the Company used € 39,867 thousand of the Revolving credit facility due 2025 and signed in 2022 by Diasorin S.p.A. for an amount equal to € 150,000 thousand. In 2023, the Chinese subsidiary was granted a line of credit and used €11,647 thousand of this line at June 30, 2024.

At 30 June 2024, IFRS 16 lease payables were € 74,224 thousand.

The Group used part of the liquidity denominated in U.S. dollars for short-term liquidity management tools (time deposits). At 30 June 2024, the value of these tools was € 47,298 thousand.

The item "hedging derivatives" includes the Fair Value of the IRS (Interest Rate Swap) hedging fluctuations of interest rates on the Term Loan, for an amount equal to € 31,086 thousand, with a negative change by € 6,380 thousand compared to 31 December 2023.

22. Provisions for employee severance indemnities

The balance in this account reflects all of the Company's pension plan obligations, other post-employment benefits and benefits payable to employees when certain requirements are met. The Group's companies provide post-employment benefits to its employees both through contributions to funds outside the Group and through defined-contribution and/or defined-benefit plans.

The manner in which these benefits are provided varies depending on the applicable statutory, tax-related and economic conditions in the countries where the Group's companies operate. As a rule, benefits are based on each employee's level of compensation and years of service.

Defined-contribution plans

The Group pays contributions to private funds or insurance companies pursuant to a statutory or contractual obligation or on a voluntary basis. With the payment of these contributions, the companies in question absolve all of their obligations. The liability for contributions payable is included under "Other current liabilities". The cost attributable to each year, which accrues based on the services provided by employees, is recognized as a "Labor cost" of the relevant organizational unit.

Defined benefit plans

The Group's pension plans that qualify as defined-benefit plans include the provisions for employee severance indemnities in Italy, the Alecta system in Sweden and the U-Kasse pension plan and Direct Covenant system in Germany.

The liability owed under these plans is recognized at its actuarial value using the projected unit credit method; actuarial gains and losses resulting from the determination of these liabilities are credited or charged to equity in the statement of comprehensive income in the year in which they arise.

Other employee benefits

The Group also provides its employees with additional long-term benefits, which are paid when employees reach a predetermined length of service. In these cases, the value of the liability recognized in the financial statements reflects the probability that these benefits will be paid and the length of time for which they will be paid. The liability owed under this plan is recognized at its actuarial value using the projected unit credit method.

It should be noted that any resulting actuarial gains or losses recorded on the basis of these employees' benefits are recognized in the income statement.

The table that follows summarizes the Group's main employee benefit plans that are currently in effect:

(in thousands of Euros)	**6/30/2024**	**12/31/2023**	**Change**
Employee benefits			
provided in:			
- Italy	3,817	3,957	(140)
- Germany	26,066	25,741	325
- Sweden	1,734	1,778	(44)
- other countries	707	837	(130)
Total employee benefits	**32,324**	**32,314**	**11**
broken down as follows:			
- Defined-benefit plans			
employee's severance indemnities	*2,314*	*2,363*	*(48)*
other defined-benefit plans	*28,414*	*28,222*	*192*
	30,728	30,585	144

- Other long-term benefits	1,596	1,729	(133)
Total employee benefits	**32,324**	**32,314**	**11**

The table below shows the main changes that occurred in the employee benefit plans compared with 31 December 2023

(in thousands of Euros)	**Defined-benefit plans**	**Other benefits**	**Total employee benefits**
Balance at 12/31/2023	**30,585**	**1,729**	**32,314**
Interest cost	563	29	592
Actuarial losses/(gains) recognized in income statement	(7)	(83)	(90)
Actuarial losses/(gains) from financial assumptions	(21)	-	(21)
Actuarial losses/(gains) from demographic changes	-	-	-
Actuarial losses/(gains) from experience	-	-	-
Current service cost	245	48	293
Benefits paid	(594)	(122)	(717)
Translation differences and other changes	(41)	(4)	(45)
Balance at 6/30/2024	**30,729**	**1,596**	**32,324**

23. Provisions for risks and charges

The item amounted to € 27,031 thousand at 30 June 2024 (€ 27,700 thousand at 31 December 2023) and refer to provisions set aside for pending disputes, risks considered as likely, and provisions for employee severance indemnities.

The table below lists the change in provisions for risks and charges:

(in thousands of Euros)	**6/30/2024**	**12/31/2023**
Opening balance	**27,700**	**30,272**
Provisions for the period	410	997
Utilizations of /Reversals for the period	(1,250)	(2,616)
Translation differences and other changes	171	(953)
Closing balance	**27,031**	**27,700**

Utilizations of the period refer to the release of a provision in December 2023 for employee and agent severance indemnities for termination of agent contracts.

24. Other non-current liabilities

Other non-current liabilities totaled € 10,677 thousand at 30 June 2024, down from the first half of 2023 (€ 10,740 thousand at 31 December 2023).
The item includes the recognition of a liability, equal to € 5,011 thousand, relating to the appreciation of a long-term debt arising from put/call option rights under the Joint Venture agreement signed with partners of the Chinese investee company, recognized according to IAS 32 and IFRS 9 accounting standards. Specifically, the Joint

Venture agreement contains an obligation for the Group to purchase its own equity instruments for cash or other financial asset and gives rise to a financial liability for the present value of the redemption amount.
The liability was initially recognized at the present value of the exercise price estimated at € 6,107 thousand and subsequent changes recognized with the offsetting entries posted to the Group's shareholders' equity. Reference is made to note "20. Shareholders' equity".

25. Trade payables

At 30 June 2024, trade payables, which totaled € 98,667 thousand (€ 100,706 thousand at 31 December 2023), include amounts owed to external suppliers for the purchase of goods and services. The decrease equal to € 2,039 thousand refers mainly to Diasorin Italia S.p.A. and to the Group's Parent Company. There are no amounts due beyond the year.

26. Other current liabilities

Other current liabilities of € 87,571 thousand at 30 June 2024 (€ 100,364 thousand at 31 December 2023) e consist mainly of amounts owed to employees for additional monthly payments, equal to € 32,072 thousand (€ 44,373 thousand at 31 December 2023), accruals and deferred charges (contract obligations) amounting to € 13,964 thousand (€ 16,949 thousand at 31 December 2023), and contributions payable to social security and health benefit institutions for a total of € 2,845 thousand (€ 4,842 thousand at 31 December 2023).

27. Liabilities for current taxes

The balance of € 20,523 thousand at 30 June 2024 (€ 9,399 thousand at 31 December 2023) represents the current tax liability for the profit earned in the period, net of tax payments made, and amounts owed for other indirect taxes and fees. The analysis of income taxes is provided in Note 9.

28. Commitment and contingent liabilities

Guarantees provided

At 30 June 2024, the guarantees and commitments that the Group provided to third parties totaled € 23,531 thousand and include bank sureties in connection with the submission of bids in response to public calls for tenders (€ 21,797 thousand), defined-contribution pension plans held by the Swedish subsidiary (€ 1,734 thousand).

Significant commitments and contractual obligations

Significant contractual obligations include the agreements executed by the Parent company Diasorin S.p.A. with Stratec in connection with the development and production of LIAISON XL and the new LIAISON XS analyzers. As to the supply agreement, Diasorin and Stratec signed an agreement according to which Stratec shall manufacture and supply the analyzers exclusively to Diasorin. The Group has agreed to purchase a minimum number of instruments. However, the projected commitment is deemed to be significantly lower than the normal level of capital investment that would be required for current or future equipment production. As a result, net invested capital is not expected to undergo significant structural changes in the future as a result of this commitment.

Contingent liabilities

The Diasorin Group operates globally. As a result, it is exposed to the risks that arise from the complex laws and regulations that apply to the Group's commercial and manufacturing activities.

The Group believes that the amounts set aside for pending legal disputes in the corresponding provision for risks are adequate.

29. Related-party transactions

Diasorin S.p.A. engaged on a regular basis in commercial and financial transactions with its subsidiaries, which are also Group companies. These transactions, which are executed on standard market terms, consist of the supply of goods and services, including administrative, information technology, personnel management, technical support and consulting services, which produce receivables and payables at the end of the year, and financing and cash management transactions, which produce income and expenses.

These transactions are eliminated in the consolidation process and, consequently, are not discussed in this section of the Report.

The incidence of related-party transactions on the single items of the balance sheet, income statement and cash flows is not material.

The total amount owed to directors and strategic executives recognized in the income statement in the first half of 2024 was € 3,278 thousand (€ 8,818 thousand at 30 June 2023).

The compensation payable to senior managers and eligible employees (key management) is consistent with standard market terms for compensation offered to employees with a similar status.

30. Significant events occurring after 30 June 2023 and business outlook

Significant events occurring after 30 June 2024 and business outlook are provided in the specific section of the Report on Operations.

31. Material non-recurring events and transactions

Pursuant to the ESMA Communication no. 32-63-1186 of 29 October 2021, no material non-recurring transactions occurred.

32. Transactions resulting from atypical and/or unusual activities

Consistent with Consob Communication no. DEM/6064293 of July 28, 2006, the Group did not carry out atypical and/or unusual transactions as provided by the Communication, which defines as atypical and/or unusual transactions those transactions that, because of their significance/materiality, type of counterparty, purpose, method used to determine the transfer price and timing (close to the end of the year), could give rise to doubts with regard to: the accuracy/completeness of the disclosure provided in the financial statements, conflict of interests, safety of the corporate assets and protection of non-controlling shareholders.

7. Annex I: Companies of the Diasorin Group at 30 June 2024

	Head office location	Currency	Share capital (*)	Net profit/(loss) for the year (*)	Shareholders' equity in the latest approved financial statements (*)	Par value per share or partnership interest	% interest held directly	Number of shares or partnership interests held
Equity investments consolidated line by line								
Diasorin Italia S.p.A.	Saluggia (Italy)	Euro	1,000,000	84,333,441	437,900,628	1	100%	1,000,000
DiaSorin S.A/N.V.	Bruxelles (Belgium)	Euro	1,674,000	2,039,183	8,044,285	6.696	100%	249
DiaSorin Ltda	Sao Paolo (Brazil)	BRL	65,547,409	7,473,010	39,261,630	1	100%	65,547,408
DiaSorin S.A.S. Unipersonnelle	Antony (France)	Euro	960,000	814,649	9,512,176	15.3	100%	62,493
DiaSorin Iberia S.A.	Madrid (Spain)	Euro	1,453,687	1,479,565	10,246,704	6.01	100%	241,877
DiaSorin Ltd	Dartford (United Kingdom)	GBP	500	3,116,711	1,755,904	1	100%	500
DiaSorin Inc.	Stillwater (United States)	USD	1	73,743,300	1,333,318,299	0.01	100%	100
DiaSorin Canada Inc	Mississauga (Canada)	CAD	200,000	531,200	2,547,100	N/A	0%	100 Class A common shares
DiaSorin Molecular LLC	Cypress (United States)	USD	100,000	24,738,444	294,897,800	100.000	0%	1
DiaSorin Mexico S.A de C.V.	Mexico City (Mexico)	MXP	63,768,473	11,964,728	73,050,920	1	100%	49,999
DiaSorin Deutschland GmbH	Dietzenbach (Germany)	Euro	275,000	-2,479,373	5,129,296	275,000	100%	1
DiaSorin AB	Solna (Sweden)	SEK	5,000,000	5,528,615	36,284,243	100	100%	50,000
DiaSorin Ltd	Rosh HaAyin (Israel)	ILS	100	812,000	18,380,000	1	100%	100
DiaSorin Austria GmbH	Wien (Austria)	Euro	35,000	866,164	3,593,667	35,000	100%	1
DiaSorin Czech s.r.o.	Prague (Czech Republic)	CZK	200,000	6,498,000	94,911,000	200,000	100%	1
DiaSorin I.N. Limited	Dublin (Ireland)	Euro	1	1,848,101	11,800,963	0,01	100%	100
DiaSorin South Africa (PTY) Ltd	Sandton (South Africa)	ZAR	101	149,493	4,440,073	1	100%	101
DiaSorin Australia (Pty) Ltd	Sydney (Australia)	AUD	3,300,000	1,394,115	13,902,908	33,000	100%	100
DiaSorin Ltd	Shanghai (China)	RMB	22,000,000	-29,518,982	11,625,081	1	76%	16,720,000
DiaSorin Switzerland AG	Rotkreuz (Switzerland)	CHF	100,000	647,548	1,183,030	100	100%	1,000
DiaSorin Poland sp. z o.o.	Warsaw (Poland)	PLN	550,000	0	13,819,542	50	100%	11,000
DiaSorin Healthcare India Private Limited	Mumbai (India)	INR	4,700,000	2,176,990	264,782,809	10	0%	1
DiaSorin APAC Pte. Ltd.	Singapore (Singapore)	EUR	1	114,928	388,704	N/A	100%	1
DiaSorin Middle East FZ-LLC	Dubai (UAE)	AED	50,000	141,470	180,232	1,000	100%	50
Luminex Corporation Inc.	Austin (United States)	USD	25,000	-18,506,280	1,739,679,262	0,001	0%	25,000,000
Luminex 2 BV under liquidation	s'Hertogenbosch (Netherlands)	EUR	90,000	150,481	19,004,433	1	0%	90,000
Luminex Japan Ltd	Tokyo (Japan)	JPY	1	9,768,798	289,196,255	1	0%	1
Luminex Trading (Shanghai) Co. Ltd.	Shanghai (China)	RMB	455,219	2,830,621	12,763,288	N/A	0%	-
Luminex Hong Kong Co. Ltd.	Hong Kong (Hong Kong)	HKD	100	817,793	12,730,569	10	0%	10
Luminex Molecular Diagnostics, Inc.	Toronto (Canada)	CAD	10,000,000	21,249,006	127,134,017	N/A	0%	-
Nanosphere LLC	Wilmington (United States)	USD	1,000	-	-	0,001	0%	1,000,000
ChandlerTec LLC	Wilmington (United States)	USD	1,000	-	-	0,001	0%	1,000,000
Iris Biotech LLC	Wilmington (United States)	USD	1,000	-	-	0,001	0%	1,000,000
Amnis LLC	Wilmington (United States)	USD	1,000	-	-	0,001	0%	1,000,000
Equity investments valued at cost								
DiaSorin Deutschland Unterstuetzungskasse GmbH	Dietzenbach (Germania)	Euro	25,565	327,717	25,565	1	-	1

(*) Amounts stated in local currency

8. Certification to the Half-Year Condensed Consolidated Financial Statements

We, the undersigned, Carlo Rosa, in my capacity as “Chief Executive Officer”, and Piergiorgio Pedron, in my capacity as “Corporate Accounting Document Officer” of Diasorin S.p.A,

attest that,

insofar as the provisions of Article 154-*bis*, Sections 3 and 4, of Legislative Decree No. 58 of 24 February 1998 are concerned, the administrative and accounting procedures applied during the first half of 2024 to prepare the Half-Year Condensed Consolidated Financial Statements were:

a) adequate in light of the Company’s characteristics; and

b) were applied effectively.

Moreover, we attest that the Half-Year Condensed Consolidated Financial Statements:

a) were prepared in accordance with the applicable international accounting principles, as adopted by the European Union pursuant to Regulation (CE) No. 1606/2002 of the European Parliament and Council dated July 19, 2002;

b) correspond to the Company’s books of accounts and bookkeeping entries;

c) are suitable for the purpose of providing a truthful and fair representation of the statement of financial position, operating performance and cash flow of the issuer and of the companies included in the scope of consolidation.

To the best of our knowledge, the interim Report on Operations provides a reliable analysis of significant events that occurred during the first half of the year and of their impact on the Half-Year Condensed Consolidated Financial Statements, together with a description of the main risks and uncertainties for the remaining six months of the year.

The interim Report on Operations also provides a reliable analysis of information concerning transactions with related parties.

Saluggia, 29 July 2024

Signed:

The Chief Executive Officer	The Corporate Accounting Document Officer
Carlo Rosa	Piergiorgio Pedron

REVIEW REPORT ON HALF-YEAR CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

To the shareholders of Diasorin SpA

Foreword

We have reviewed the accompanying half-year condensed consolidated financial statements of Diasorin SpA and its subsidiaries (the "Diasorin Group") as of 30 June 2024, comprising the consolidated statement of financial position, consolidated income statement, consolidated comprehensive income statement, statement of changes in consolidated shareholders' equity, consolidated statement of cash flows and related notes. The directors of Diasorin SpA are responsible for the preparation of the half-year condensed consolidated financial statements in accordance with the International Accounting Standard applicable to interim financial reporting (IAS 34) as adopted by the European Union. Our responsibility is to express a conclusion on these half-year condensed consolidated financial statements based on our review.

Scope of Review

We conducted our work in accordance with the criteria for a review recommended by Consob in Resolution No. 10867 of 31 July 1997. A review of half-year condensed consolidated financial statements consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than a full-scope audit conducted in accordance with International Standards on Auditing (ISA Italia) and, consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion on the half-year condensed consolidated financial statements.

Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the half-year condensed consolidated financial statements of Diasorin Group as of 30 June 2024 are not prepared, in all material respects, in accordance with the International Accounting Standard applicable to interim financial reporting (IAS 34) as adopted by the European Union.

Milan, 2 August 2024

PricewaterhouseCoopers SpA

Signed by

Salvatore Savino
(Partner)

This report has been translated into English from the Italian original solely for the convenience of international readers. Accordingly, only the original text in Italian language is authoritative.